NewTimeSpace

Going Global Weekly Report: Pharma Firms Sealed Licensing Deals at a Fast Pace as Semiconductors and E-Commerce Accelerate toward HK Listings - 20260904

Fri, 04 Sep 2026 11:30:57 GMT

Outbound M&A

1.MAN WAH HLDGS (01999.HK): On August 31, announced the acquisition of 7,684,126 shares of UK-based DFS, representing approximately 3.26% of DFS's issued shares, from Man Wah Wong Family Investment Limited for a consideration of GBP 12.4713 million (approximately HKD 132 million), lifting its stake to approximately 8.58% upon completion. DFS is a UK upholstered furniture retailer listed on the London Stock Exchange, which recorded revenue of GBP 1.03 billion in FY2025.

Outbound Partnerships

1.HUTCHMED (00013.HK): On September 3, announced that its subsidiary had entered into an exclusive development and licensing agreement with a GSK affiliate for HMPL-A830, a KRAS-EGFR antibody-targeted conjugate drug, granting rights to develop and commercialize the drug globally excluding Mainland China, Hong Kong SAR, Macao SAR and the Taiwan region, for an upfront payment of USD 110 million and development, regulatory and commercial milestone payments totalling up to USD 1.295 billion, plus royalties based on net sales; a global Phase I clinical trial is expected to commence in the second half of 2026.

2.SBP GROUP (01177.HK): On August 31, announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. had entered into an exclusive licensing and supply agreement with Cipla for TQB2102, a HER2 bispecific antibody-drug conjugate, under which Cipla is licensed to develop and commercialize the drug in India, South Africa and five other emerging markets, entitling the group to up to USD 123 million in milestone payments plus double-digit royalties. This is the second regional licensing collaboration concluded for TQB2102.

3.KEYMED BIO-B (02162.HK): On September 2, signed an exclusive licensing agreement with Aeira Pte. Ltd. covering registration and commercialization of its self-developed IL-4Rαmonoclonal antibody, stapokibart injection (Kangyueda), in 18 countries and regions, including 11 Southeast Asian countries, 5 Central Asian countries and the Hong Kong and Macao SARs. The company will receive upfront payments, milestone payments and high-double-digit sales-based royalties.

4.PEGBIO CO-B (02565.HK): On September 2, entered into a material transfer agreement with South Korea's SN BioScience to apply its SNA long-acting delivery platform to three peptide drug candidates for metabolic diseases, including APGP6, for joint long-acting development studies.

Outbound Financing

1.SHEIN-W (00625.HK): On August 31, announced the results of its global offering at a final offer price of HKD 48.56 per share, with 279,992,500 Class B shares offered in total, raising approximately HKD 13.596 billion in gross proceeds and approximately HKD 13.214 billion in net proceeds; the shares commenced trading on The Stock Exchange of Hong Kong on September 1.

2.ANJI TECHNOLOGY (688019.SH): On September 3, submitted an application to HKEX for the issuance and listing of H shares.

3.AMLOGIC (688099.SH): On September 1, its H-share issuance received filing with the China Securities Regulatory Commission (CSRC), with a proposed issuance of no more than 53,815,500 H shares.

4.LONGSYS (09976.HK): On September 4, fixed the offer price for its H-share global offering at HKD 236.00 per share, offering 26,077,800 H shares, with listing expected on September 8.

Regulation and Compliance

1.SBP GROUP (01177.HK): On September 3, announced that TQB6426, a national Class 1 innovative drug and a GPC3-targeting antibody-drug conjugate independently developed by its subsidiary Chia Tai Tianqing, had received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for advanced malignant tumors. GPC3 is highly expressed in hepatocellular carcinoma, and no GPC3-targeting ADC has been approved for marketing worldwide.

Overseas Orders and Contract Wins

1.HONGHUA GROUP (00196.HK): On September 2, announced that its subsidiary Sichuan Honghua Petroleum Equipment Co., Ltd. had signed drilling rig sales agreements with a Middle East customer aggregating RMB 600 million, under which it will supply several large drilling rigs equipped with self-developed intelligent equipment, including automated tools and the Opera smart drilling system.

Overseas Operating Data

1.BYD COMPANY (01211.HK): On September 1, disclosed August sales of 440,300 new energy vehicles, of which 189,500 were exports.

2.GEELY AUTO (00175.HK): On September 1, disclosed total sales of 270,200 units in August, up 8% year on year, with ZEEKR-brand sales up 110% year on year and exports up 205% year on year.

NewTimeSpace Overseas Watch

This week's overseas hotspots centered on two fronts: pharmaceutical asset licensing and Hong Kong listings. Drugmakers are out-licensing self-developed pipelines through regional or even global exclusive agreements, with deals generally structured as upfront payments plus milestone payments and sales-based royalties, and licensed territories extending from emerging markets such as India and South Africa to Southeast Asia, Central Asia and global scope, while differentiated targets such as GPC3 ADCs are beginning to draw collaborations with multinational drugmakers. On the financing front, cross-border e-commerce and A-share semiconductor and memory companies are concentrating on or advancing H-share listings in Hong Kong, with both single-project fundraising scale and the density of H-share offerings rising in tandem. The observations show that pharma going global is evolving from one-off clinical approvals toward scaled global rights licensing, equipment manufacturers are locking in incremental demand in markets such as the Middle East through large orders, and automakers' exports continue to grow, as the going-global model shifts from product exports toward a balance of rights deals and capital market operations.

This article is for information organization only and does not constitute any investment advice.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

SBP GROUP (01177.HK): FDA Approves IND Application for Self-Developed Class 1 Drug TQB6426 "GPC3 ADC" for Advanced Malignant Tumors

Thu, 03 Sep 2026 13:26:28 GMT

NewTimeSpace News: On September 3, 2026, Sino Biopharmaceutical Limited (stock code: 01177) announced that TQB6426, a national Class 1 innovative drug and a GPC3-targeting antibody-drug conjugate (ADC) independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., had received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the treatment of advanced malignant tumors.

GPC3 is a glycoprotein located on the cell membrane that is barely expressed in normal adults but highly expressed in hepatocellular carcinoma (HCC), where it serves as a clinical diagnostic biomarker, and is also upregulated in lung squamous cell carcinoma and ovarian cancer. No GPC3-targeting ADC has been approved for marketing worldwide, with peer candidates generally in preclinical or early clinical exploration. Preclinical data showed that TQB6426 demonstrated solid target-binding capacity and tumor-cell-specific killing, with potent bystander killing activity and in-vivo antitumor activity in animals outperforming comparable products, indicating best-in-class (BIC) development potential. As an ADC, TQB6426 uses its GPC3-targeting antibody to deliver a cytotoxic payload precisely to tumor cells and extends killing to GPC3-negative tumor cells through a potent bystander effect, overcoming tumor heterogeneity and broadening antitumor coverage.

Liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death, with 870,000 new cases and 760,000 deaths globally in 2022, projected to nearly double to 1.52 million new cases and 1.37 million deaths by 2050 in the absence of effective interventions, with China accounting for approximately 42.4% of global cases. The disease is insidious in onset and progresses rapidly, with approximately 64% of patients diagnosed at intermediate or advanced stages and a 5-year recurrence rate of as high as 70% even after curative resection in early-stage patients. The group will accelerate the Phase I clinical trial of TQB6426 to assess its safety, tolerability, pharmacokinetic profile and preliminary efficacy in patients with advanced malignant tumors, with the aim of providing new treatment options for patients with hepatocellular carcinoma and other solid tumors globally.

View announcement.

CMS (00867.HK): China NDA Approval for Ruxolitinib Phosphate Cream in Atopic Dermatitis Adds a Second Indication

Thu, 03 Sep 2026 10:45:49 GMT

NewTimeSpace News: On September 3, 2026, China Medical System Holdings Limited (stock code: 00867) announced that the New Drug Application (NDA) of ruxolitinib phosphate cream (Bailutuo) for mild-to-moderate atopic dermatitis (AD), developed by its subsidiary Dermavon Holdings Limited (Dermavon), an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, had been approved by the National Medical Products Administration (NMPA) on September 2, 2026, with the drug registration certificate obtained on September 3. The NDA was included in the priority review list for pediatric-friendly new products, dosage forms and specifications matching children's physiological characteristics, which shortened the review cycle.

The product is indicated for the short-term and non-continuous chronic topical treatment of mild-to-moderate AD in immunocompetent children aged 2 years and above and adults, where other topical therapies are inadequately controlled or not recommended. In a Phase III clinical study in China, 63.0% of patients treated for 8 weeks achieved an Investigator's Global Assessment (IGA) score of 0 or 1 with an improvement of at least 2 points from baseline, versus 9.2% for placebo (P<0.001), and 78.0% achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI 75), versus 15.4% for placebo (P<0.001).

In January 2026, ruxolitinib phosphate cream received China NDA approval as the first topical JAK inhibitor approved in China for vitiligo, and the AD approval extends the product to a second indication. It is estimated that China had more than 54 million AD patients in 2024, with mild-to-moderate cases accounting for 98%, or more than 52.5 million patients. Dermavon has built a comprehensive treatment-plus-care solution for AD, spanning Bailutuo (mild-to-moderate disease), comekibart injection (MG-K10) (moderate-to-severe disease), oral small-molecule targeted drug CMS-D001 (moderate-to-severe disease) and the Heling soothing product line, which is expected to synergize with Dermavon's commercialized innovative drug ILUMETRI (tildrakizumab injection) and exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) in expert networks and market resources.

On December 2, 2022, the group through Dermavon entered into a collaboration and license agreement with Incyte, obtaining exclusive rights to develop, register and commercialize ruxolitinib phosphate cream in Mainland China, Hong Kong SAR, Macao SAR, the Taiwan region and 11 Southeast Asian countries, together with non-exclusive rights to manufacture the product within the territory. Incyte retains global development and commercialization rights and markets the product as Opzelura in the United States and Europe, where it was the first topical JAK inhibitor approved by the US FDA.

View announcement.

KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia

Wed, 02 Sep 2026 13:40:42 GMT

NewTimeSpace News: On 2 September 2026, Keymed Biosciences Inc. (stock code: 02162.HK) announced, on a voluntary basis, that the Company had signed an exclusive license agreement with multinational pharmaceutical company Aeira Pte. Ltd. (Aeira) to collaborate on the registration and commercialization of Stapokibart injection (trade name: Kangyueda), an IL-4Rα-targeting monoclonal antibody developed in-house by the Company, in Southeast Asia and Central Asia.
Under the agreement, Keymed will receive an upfront payment, milestone payments upon approval of marketing applications in different countries and commercialization milestone payments, and is entitled to royalties of up to high-double-digit rates calculated on the net sales of the product in the licensed territories.
Aeira will be responsible for the regulatory filings and commercialization of Stapokibart in 11 countries in Southeast Asia (Brunei Darussalam, Cambodia, Indonesia, the Lao People's Democratic Republic, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste and Vietnam), 5 countries in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan), and the Hong Kong Special Administrative Region and the Macao Special Administrative Region — 18 countries and regions in total. Keymed will continue to be responsible for the manufacture and supply of Stapokibart for Aeira.
Stapokibart (trade name: Kangyueda, R&D codename: CM310) is the first domestically developed IL-4Rα antibody drug granted marketing approval by the NMPA, with its indications for moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis approved for marketing in September 2024, December 2024 and February 2025, respectively. The collaboration marks an important milestone in Keymed's internationalization strategy for innovative biologics, leveraging the partner's unique commercial networks and registration experience in Southeast Asia and Central Asia to accelerate the launch and commercialization of Stapokibart in these regions.

View announcement.

KEYTOP PARKING (02272.HK): Files Application for H-Share Full Circulation, Plans to Convert All 2,857,040 Unlisted Shares into H Shares on the Main Board

Wed, 02 Sep 2026 11:45:32 GMT

NewTimeSpace News: On 2 September 2026, KEYTOP PARKING INC. (stock code: 02272.HK) announced that it had filed an application with the China Securities Regulatory Commission (CSRC) on the same day to convert all of its 2,857,040 issued unlisted shares, with a par value of RMB 1.0 each, into H shares with a par value of RMB 1.0 each to be listed on the Main Board of the Stock Exchange of Hong Kong (the H-share full circulation).
The application was made pursuant to the Guidelines on Full Circulation of Unlisted Domestic Shares of H-share Companies, issued by the CSRC on 14 November 2019 and further amended on 10 August 2023. Upon obtaining all relevant approvals (including filing with and/or obtaining approval from the CSRC and the Stock Exchange) and complying with all applicable laws, regulations and rules, such unlisted shares will be converted into H shares, and the company will apply for approval for the listing of and dealing in such H shares on the Main Board of the Stock Exchange.
Under the company's articles of association, no further shareholders' meeting is required to approve the conversion and listing. As of the date of this announcement, details of the implementation plan for the conversion and listing have not yet been finalized, and the company will publish further announcements on progress in due course in accordance with the Listing Rules and the inside information provisions. Completion of the H-share full circulation and the conversion and listing is subject to the fulfillment of other relevant procedures required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulators.

HAIXI PHARMA (02637.HK): Oral Retinal Disease Drug HX9428 Files Phase IIa IND for Diabetic Macular Edema; Phase I Data in nAMD Disclosed

Wed, 02 Sep 2026 11:32:38 GMT

NewTimeSpace News: On 2 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (stock code: 02637.HK) announced that HX9428, a candidate molecule under its self-developed innovative drug program HXP056, submitted a Phase IIa investigational new drug (IND) application for diabetic macular edema (DME) to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) on 31 August 2026, making DME the second indication being advanced for HX9428.
The Phase I dose-escalation study for the first indication, neovascular age-related macular degeneration (nAMD, also known as wet AMD), has been fully completed, enrolling 15 patients across five dose levels of 5-40 mg/QD. Of these, 13 patients (including 3 treatment-naive patients and 10 previously treated with anti-VEGF therapy) completed the planned 24 weeks of dosing without any additional intravitreal anti-VEGF injections; best-corrected visual acuity (BCVA) improved by more than 5 letters on average across the overall population, with the 3 treatment-naive patients improving by an average of 12 letters. Interim Phase I data as of February 2026 were published in the abstract of the 2026 American Academy of Ophthalmology (AAO) meeting, and HX9428 has received Fast Track Designation (FTD) from the US FDA, with Phase II studies in nAMD ongoing concurrently in China and the United States.
HX9428 is a novel oral small-molecule drug developed in-house for vascular retinal diseases including nAMD, DME and RVO. Current anti-VEGF therapy requires intravitreal injection, and oral administration is expected to offer patients a more convenient alternative. The company listed on the Main Board of the Hong Kong Stock Exchange in October 2025.

View announcement.

HONGHUA GROUP (00196.HK): Subsidiary Signs Drilling Rig Sales Agreement Worth RMB 600 Million with Middle East Customer

Wed, 02 Sep 2026 09:14:07 GMT

NewTimeSpace News: On 2 September 2026, Honghua Group Limited (stock code: 00196) announced that its subsidiary Sichuan Honghua Petroleum Equipment Co., Ltd. has recently signed drilling rig sales agreements with a Middle East customer totalling RMB 600 million, under which Sichuan Honghua will supply several large drilling rigs.

According to the announcement, the rigs will be equipped with the Company's self-developed automated tools and Opera intelligent drilling system, enhancing drilling efficiency and the automation and intelligence level of the rigs.

PEGBIO CO-B (02565.HK): Enters Joint R&D Collaboration with SN BioScience for Long-Acting Metabolic Disease Peptides

Wed, 02 Sep 2026 09:03:15 GMT

NewTimeSpace News: On 2 September 2026, PegBio Co., Ltd. (stock code: 02565) announced that it has entered into a material transfer agreement with SN BioScience, Inc., a Korean biotech company, under which SN BioScience will apply its self-developed serinol nucleic acid (SNA) long-acting drug delivery platform to three of the Group's self-developed innovative metabolic disease peptide candidates, including APGP6, with joint research to be conducted on formulation and long-acting delivery of the candidates.

According to the announcement, the collaboration covers three drug candidates at once rather than a single product, allowing parallel validation of the technical fit between the SNA platform and the Group's next-generation peptide assets, and exploring the potential to extend duration of action, optimise dosing regimens and improve overall product profiles.

LAEKNA-B (02105.HK): First subject enrolled in Phase I clinical study of LAE118 for advanced solid tumours

Tue, 01 Sep 2026 01:04:02 GMT

NewTimeSpace News: On 1 September 2026, Laekna, Inc. (stock code: 02105) announced that the Group has initiated subject recruitment for the Phase I clinical study of LAE118 for the treatment of advanced solid tumours in China, with the first subject enrolled. LAE118 is a novel PI3Kα pan-mutation selective inhibitor independently developed by the Group, which has obtained investigational new drug (IND) approval from the US FDA and the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration as of the date of this announcement.

In June 2026, the Group entered into an exclusive licence agreement with Vasque Bio, Inc. Under the agreement, the Group is entitled to receive upfront and milestone payments of up to USD 527 million in aggregate, which are non-refundable and non-creditable, as well as tiered sales royalties of single-digit to double-digit percentages of the future net sales of LAE118 in the licensed territory. The Group is also entitled, without additional consideration, to equity interests of up to high double-digit percentages of the issued ordinary shares of Vasque Bio, or cash payments in lieu of such ordinary shares. If Vasque Bio completes an eligible strategic cooperation or acquisition transaction meeting certain conditions related to the use of LAE118, the Group will be entitled to additional payments of up to 50% of the value of such strategic transaction.

Vasque Bio is a US-based clinical-stage biotechnology company focused on developing innovative therapies for serious rare diseases, supported by a consortium of leading life science investors including The Column Group (TCG) and F-Prime, while the Group focuses on developing LAE118 as an oncology therapy outside the licensed territory. The Company noted that LAE118 may ultimately not be successfully developed and commercialised.

SBP GROUP (01177.HK): Enters Exclusive Licensing Agreement with Cipla for TQB2102, with Deal Value Up to USD 123 Million

Mon, 31 Aug 2026 10:49:13 GMT

NewTimeSpace News: On August 31, 2026, Sino Biopharmaceutical Limited (stock code: 01177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) has entered into an exclusive license and supply agreement with Cipla Limited (Cipla) for TQB2102 (rolditamig deuderuxtecan), the Group's self-developed HER2 bispecific antibody-drug conjugate (ADC).

According to the announcement, this is the second regional licensing collaboration for TQB2102, and the two collaborations have together brought the Group approximately USD 30 million in upfront and milestone payments to date. Under the agreement, the Group will grant Cipla an exclusive license to develop and commercialize TQB2102 in India, South Africa and five other emerging markets (the licensed territories). Cipla will be responsible for local clinical development, regulatory filings and commercialization in the licensed territories, while CTTQ will continue to be responsible for the manufacture and supply of TQB2102. The Group is entitled to upfront payments and potential development, regulatory and sales milestone payments of up to USD 123 million, plus double-digit royalties based on TQB2102's annual net sales.

TQB2102 is a next-generation HER2 biparatopic bispecific antibody-drug conjugate developed by the Group, targeting both the ECD II and ECD IV domains of HER2. Phase Ib results presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed an overall response rate (ORR) of 53.4% (39/73) in advanced HER2-low breast cancer, with an interstitial lung disease (ILD) incidence of 0.55%. The drug has received three breakthrough therapy designations from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, and multiple Phase III studies are ongoing; the Group will present Phase III data in HER2-low breast cancer as a late-breaking abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting.

Founded in 1935, Cipla is a global pharmaceutical company with 48 manufacturing sites, operating in more than 70 markets worldwide and ranking as India's third-largest pharmaceutical company. The Group stated that the collaboration leverages Cipla's local capabilities and market access advantages in the licensed territories to advance the Group's internationalization strategy, and is expected to improve the global accessibility of TQB2102.

The source of this information is the HKEX announcement.

Going Global Weekly Report: Innovative Drugs Win Dense FDA Clearances; SHEIN and Mech-Mind Lead the Hong Kong Listing Wave - 20260828

Fri, 28 Aug 2026 10:02:27 GMT

Outbound M&A

1. GUSHENGTANG (02273.HK): Announced on 27 August that its subsidiary Gushengtang Malaysia Sdn. Bhd. entered into sale and purchase agreements with the shareholders of three Malaysian traditional Chinese medicine (TCM) institutions to acquire 100% of YC TCM (Taman Segar) Sdn. Bhd., YC TCM Sdn. Bhd. and SWS Medical Sdn. Bhd., all of which are primarily engaged in TCM consultation and treatment services. Upon completion, the targets will be consolidated into the group's consolidated financial statements. The consideration will be funded by the net proceeds from the placement and convertible bonds and idle funds, and the transactions do not constitute connected transactions.

Outbound Cooperation

1. WAI CHUN BIOTEC (00660.HK): Announced on 26 August the signing of strategic cooperation memoranda of understanding with multiple parties for the integrated AI digital infrastructure ecosystem project at the Pahang Aerotropolis in Malaysia, with a master planned area of over 1,200 acres and an initial-phase IT load of 300 MW.

2. YANCOAL AUS (03668.HK): Announced on 24 August an increase in the annual cap under its Glencore framework coal sales agreement for the year ending 31 December 2026 from USD 350 million to USD 750 million, mainly due to expanded spot coal purchase demand amid Middle East conflicts and higher HVO spot sales; first-half transaction value totaled approximately USD 215 million.

Overseas Projects and Operations

1. CHINA BAOLI TEC (00164.HK): Announced on 26 August that its Mongolian iron ore project has entered the construction phase: the project partner has completed procurement of core equipment and shipped it to the mine site, and the company has dispatched a technical expert team to assist with installation and commissioning, with the first batch of processed iron ore concentrate expected shortly; infrastructure for its Mongolian coal mine project has been completed and recruitment has commenced.

2. JIAXIN INTL RES (03858.HK): Announced on 25 August that its subsidiary ZV, through public tender, entered into a mining construction contract with CCECC's Kazakhstan branch for the expansion of No. 1 tailings storage facility under the Bakuta tungsten mine project, with an initial contract price of approximately RMB 257 million (tax inclusive) and a cap of approximately RMB 306 million.

Overseas Orders and Contract Wins

1. MOBI DEV (00947.HK): Announced on 27 August that, during the 2026 FIFA World Cup in the US, Canada and Mexico, it will supply high-performance multi-beam antenna products for three World Cup venues in Mexico in partnership with local operators, with an estimated initial collaboration of over USD 1 million and continued signal coverage support for densely populated areas of Mexico thereafter.

2. PATEO (02889.HK): Announced on 26 August that it has entered the global supply system of a leading international automotive group for the first time, winning program awards across the customer's global models of a premium luxury brand and the export models of a mid-to-high-end brand, covering core overseas markets including Europe, the Middle East and South America, supplying high-end intelligent cockpit domain controllers built on Qualcomm's fourth-generation Snapdragon 8295 platform along with AI in-vehicle interaction systems.

Outbound Financing

1. SHEIN-W (00625.HK): Launched its global offering on 24 August, initially offering 279,992,500 Class B shares, comprising 27,999,300 shares in the Hong Kong public offering and 251,993,200 shares in the international offering, at a maximum offer price of HKD 49.50 per share, with Goldman Sachs, Morgan Stanley and JPMorgan as joint sponsors.

2. LEADERDRIVE (688017.SH): On 26 August, its board of directors approved a resolution to issue H-shares and list on the Main Board of The Stock Exchange of Hong Kong Limited, aimed at deepening its global strategic layout; the proposal remains subject to shareholder approval and filing/approval by the CSRC, the Stock Exchange and other regulators.

3. LONGSYS: Passed the HKEX listing hearing, with CITIC Securities Co., Ltd. and Citi as joint sponsors; the company was the world's second-largest independent semiconductor memory manufacturer by 2025 storage product revenue.

4. Mech-Mind Robotics (09615.HK): Launched its global offering on 24 August, initially offering 23,140,590 H-shares, comprising 1,157,040 shares in the Hong Kong public offering and 21,983,550 shares in the international offering, at a maximum offer price of HKD 101.70 per share.

5. Nazhen Technology: Received CSRC filing for overseas listing, planning to issue up to 310,855,000 overseas-listed ordinary shares on The Stock Exchange of Hong Kong Limited.

Regulatory and Compliance

1. CSPC PHARMA (01093.HK): Announced on 26 August that its PD-1/IL-15 bispecific fusion protein SYS6090 has been granted Fast Track designation by the US FDA for the treatment of MSS or pMMR metastatic colorectal cancer that has progressed after prior standard therapy.

2. CSPC PHARMA (01093.HK): Announced on 25 August that its recombinant respiratory syncytial virus (RSV) vaccine SYS6057 has been cleared by the US FDA to initiate clinical trials for the prevention of RSV-associated lower respiratory tract disease in people aged 60 and above.

3. BAO PHARMA-B (02659.HK): Announced on 24 August that KJ015, a subcutaneous formulation of a HER2-targeting bispecific antibody, has been cleared by the US FDA to initiate clinical trials.

4. ANTENGENE-B (06996.HK): Announced on 25 August that the Phase I ATTRACT study of its CD19/CD3 bispecific T-cell engager antibody ATG-201 has been approved by an Australian Human Research Ethics Committee.

NewTimeSpace Going-Global Observations

Main-line assessment: This week, two clear threads run through Chinese companies' global expansion—dense regulatory clearances for innovative drugs overseas, and a renewed heating-up of the Hong Kong listing and financing channel.

1. Pharmaceutical going-global enters a regulatory payoff period: Multiple self-developed drugs from CSPC PHARMA, BAO PHARMA and ANTENGENE have successively received clinical or qualification recognition from the US FDA and Australian regulators, with targets spanning bispecific antibodies, fusion proteins, vaccines and cell engagers; pipeline structures continue to diversify, and the going-global echelon is shifting from single-product breakthroughs to clustered pipeline advancement.

2. The structure of Hong Kong financing vehicles is broadening: SHEIN and Mech-Mind have launched global offerings, LONGSYS has passed its listing hearing, and LEADERDRIVE and Nazhen Technology are advancing H-share processes; going-global players are extending from traditional manufacturing and resources to technology and consumer platforms such as fashion e-commerce, robotics and semiconductor memory, visibly widening the industry coverage of the capital channel.

3. Resources and orders are advancing overseas in tandem: Mongolia's iron ore project has entered the construction phase and the Kazakhstan tungsten tailings facility contract has been signed, moving resource projects from exploration and planning into construction and output; the World Cup venue antenna supply in Mexico and global program awards from a leading automaker show that the overseas penetration of communications and intelligent cockpit supply chains is strengthening in tandem.

Trend wrap-up: Overall, the focus of going-global is shifting from single-product and engineering exports to multidimensional coordination of technology, capital and channels, with the industry structure showing a differentiated pattern of technology and pharmaceuticals leading while resources and manufacturing underpin.

This article is for information compilation only and does not constitute investment advice.

WEI YUAN HLDG (01343.HK): Accepts JTC Consent Letter for Redevelopment of New Headquarters in Singapore, Plot Ratio Raised to 1.40

Fri, 28 Aug 2026 09:33:23 GMT

NewTimeSpace News: On 28 August 2026, Wei Yuan Holdings Limited (stock code: 01343) announced that WGC, an indirect wholly-owned subsidiary of the Company and the lessee of the property, had submitted a letter of acceptance to JTC, confirming acceptance of all terms and conditions in the consent letter issued by JTC in respect of the proposed redevelopment works at the property intended for the Group's new headquarters.

According to the announcement, the property is a leasehold industrial site together with buildings erected thereon at 18 Chin Bee Drive, Singapore 619865, leased from JTC, a statutory board under the Ministry of Trade and Industry of Singapore responsible for industrial development, for a term of 20 years commencing from 26 April 2025, to be used as the Group's headquarters comprising offices, warehouse and dormitory. The redevelopment works mainly involve partial demolition of existing buildings and other structures and construction of new buildings and structures in accordance with a new aggregate plot ratio of 1.40 (calculated on a combined basis for two land lots within the property, higher than the existing aggregate plot ratio of 0.85 and 0.90 respectively), together with installation of solar panels in accordance with applicable requirements.

JTC issued the consent letter dated 17 August 2026, granting consent to the redevelopment works subject to the terms and conditions contained therein, which were required to be accepted by WGC on or before 31 August 2026. WGC submitted the letter of acceptance on 28 August 2026. Key terms include completion of the redevelopment works within two years from the date of the consent letter and compliance with the aggregate plot ratio requirement; if the actual aggregate plot ratio of the completed redevelopment falls below the existing aggregate plot ratio, the Group will be required to return the property to JTC and pay compensation calculated by reference to the replacement value of existing structures, and failure to complete the works in accordance with the consent letter will be treated as a breach of the lease, entitling JTC to exercise rights or remedies including repossession of the property.

Having considered all terms and conditions of the consent letter, the aggregate plot ratio increase upon completion and the better fit of the redevelopment versus renovation of existing buildings, the directors consider that acceptance of the consent letter is in line with the Group's plans for the property and in the interests of the Company and its shareholders as a whole. As of the date of the announcement, the Group has not entered into any construction contract or engaged any contractor, nor obtained any quotation or tender for the redevelopment works, and will commence the contractor selection process; subject to the final terms and contract sum of the construction contract, the redevelopment works may constitute a discloseable transaction under Chapter 14 of the Listing Rules, and the Company will publish further announcement(s) in due course.

Wai Chun Bio-Technology (00660.HK): Signs MOU for Strategic Cooperation on AI Data Centre in Pahang Aviation City, Malaysia

Tue, 25 Aug 2026 23:53:47 GMT

NewTimeSpace News: On August 25, 2026,Wai Chun Bio-Technology(00660.HK) announced that on August 25, 2026, the Company entered into a memorandum of understanding for strategic cooperation with PACDB, Baiyuzen, Ennova and Radiant in respect of the integrated AI digital‑infrastructure ecosystem project in Pahang Aviation City, Malaysia. The overall planned site area exceeds 1,200 acres, among which the first‑phase site covers approximately 253.74 acres with a planned IT load of 300 MW. Core developments include large‑scale AI data centres, GPU computing‑power infrastructure, AI supercomputing platforms, green‑energy facilities and optical‑fibre networks.

According to the announcement, as a core consortium member, the Company will take deep part in core‑technology delivery and capital operations for the project, including providing AI‑technology and computing‑power infrastructure support, introducing global industrial‑cooperation channels, leading RWA tokenisation of data‑centre assets and pursuing Hong‑Kong‑listing arrangements. The cooperating parties are expected to spearhead investment and financing of approximately USD 200 million and USD 600 million for the project respectively.

Jiaxin International Resources (03858.HK): Signs Bakuta Mining Construction Contract Worth Approximately RMB 257 Million

Tue, 25 Aug 2026 00:38:16 GMT

NewTimeSpace News: On August 24, 2026, Jiaxin International Resources (03858.HK) announced that its subsidiary ZV signed the Bakuta Mining Construction Contract with CCECC Kazakhstan Branch on August 24, 2026 for the expansion works of the No.1 tailings pond, covering tailings dam construction, anti‑seepage facilities for the pond area, tailings transportation facilities and other works. The service period is 575 calendar days commencing from the effective date of the contract or the date specified in the notice to commence works, with the scheduled completion date on 22 April 2028.

As stated in the announcement, the initial contract price is approximately RMB 257 million (tax‑included), and the final contract price shall not exceed around RMB 306 million.

YANCOAL AUS (03668.HK): Raises Annual Cap under Glencore Coal Sales Framework Agreement to USD 750 Million

Mon, 24 Aug 2026 09:11:22 GMT

NewTimeSpace News: On 24 August 2026, Yancoal Australia Ltd (stock code: 03668) announced that the annual cap for transactions under the Glencore framework coal sales agreement for the year ending 31 December 2026 has been revised from USD 350 million to USD 750 million, with all other terms of the agreement unchanged.

The announcement attributed the increase mainly to market turmoil caused by the Middle East conflict, which expanded the likelihood of Glencore purchasing coal on the spot market, and increased spot sales by HVO Coal Sales Pty Ltd in the first half of 2026, requiring sufficient headroom under the cap to sustain transactions through to the end of 2026. Transaction volume under the agreement for the six months ended 30 June 2026 was approximately USD 215 million. As Glencore's wholly-owned subsidiary Anotero Pty Ltd holds a 49% interest in the Company's subsidiaries and a 49% participating interest in the Hunter Valley joint venture, Glencore is a connected person of the Company; the revised cap is only subject to reporting, announcement and annual review requirements, and is exempt from independent shareholders' approval.

SUNSHINE OIL (02012.HK): Subsidiary Holds 40% Stake in New Joint Venture to Build 6,000P Computing Power Centre

Sun, 23 Aug 2026 11:13:02 GMT

NewTimeSpace News: On 23 August 2026, Sunshine Oilsands Ltd. (02012.HK) voluntarily announced that its wholly-owned subsidiary, Sangxiang Petrochemical (Shanghai) Co., Ltd., together with Jiangsu Zhongke Supply Chain Management Co., Ltd., Shenzhen Sahara Hengxin Family Management Co., Ltd., Shanghai Chenzhixin New Energy Technology Co., Ltd., Shanghai Linweishuchen Technology Co., Ltd. and Shanghai Bespavo Energy Technology Co., Ltd. (collectively the JV partners), jointly invested to establish Deneng Zhisuan Artificial Intelligence (Beidaihe) Co., Ltd. in the Beidaihe District of Qinhuangdao City, with Sangxiang Petrochemical holding a 40% stake.

The AI computing power centre project leverages the Beidaihe government's existing power equipment systems and existing land and properties, combined with low-cost cooling energy provided by third parties, to build a 6,000P computing power centre. The project has received strong support from the Beidaihe government, covering project approval, permits for projects under construction and comprehensive supporting services; in addition, a government-controlled enterprise in Beidaihe will subsequently take an equity stake in the project. Once built and operational, the project will change the company's single business and profit model, bringing new profit growth points and laying a solid foundation for the company's entry into the AI track.

The company is a listed company headquartered in Calgary, listed on the Hong Kong Stock Exchange on 1 March 2012, focused on developing its significant oil sands lease interests in the Athabasca oil sands region, where it holds approximately one million acres of oil sands and oil and gas lease interests; it is focused on achieving milestone development targets in the West Ells project area, with an initial production target of 5,000 barrels per day.

Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821

Fri, 21 Aug 2026 10:40:53 GMT

Overseas Cooperation

1. HENLIUS (02696.HK) disclosed on August 17 that it entered into a cooperation framework agreement with Sandoz AG of Switzerland, covering full-chain collaboration on up to 10 biosimilars of monoclonal antibodies and antibody-drug conjugates across the global market excluding Mainland China, Hong Kong, Macao and Taiwan—spanning CMC development, clinical development, regulatory filings through to manufacturing, launch, commercialization and lifecycle management. The first batch of cooperation products comprises cetuximab biosimilar HLX05-N, evolocumab HLX16 and belimumab biosimilar. Sandoz will pay upfront payments aggregating no more than USD 77 million, development milestones and development budget milestones aggregating no more than USD 160 million, and sales milestones aggregating no more than USD 77 million, with milestones plus upfront payments totaling up to USD 314 million; additionally, Sandoz will pay a 40% share of net sales or net profit in the cooperation territories, and a non-refundable option fee of USD 8 million for hyaluronidase HLXTE-HAase1001. Billable amounts of no more than USD 100.5 million are expected to be achieved in 2026.

2. 5100 XIZANG (01115.HK) disclosed on August 19 that its wholly-owned subsidiary entered into a distribution contract with Landmark Holding Sdn. Bhd. of Malaysia, granting exclusive distribution rights for 5100 mineral water in Malaysia and non-exclusive distribution rights for Southeast Asian and Middle East export markets, with an initial cooperation term of three years, automatically renewable for three years upon meeting performance targets.

3. SHOUGANG CENT (00103.HK) disclosed on August 17 that it signed a letter of intent for cooperation with Meili Jingjie Capital, proposing to jointly establish a joint venture in the tyre carcass material sector and expand the global industrial rayon product market; Meili Jingjie Capital is the controlling shareholder of Cordenka, a global industrial rayon producer. The formal agreement remains subject to negotiation and signing.

4. GAUSH MEDITECH (02407.HK) disclosed on August 17 that its subsidiary Gaoshi Innovation signed a five-year exclusive agency agreement with HEIDELBERG ENGINEERING GmbH of Germany, under which HEIDELBERG will exclusively distribute Gaoshi Innovation's self-developed corneal confocal microscope T3 globally outside China, and handle marketing and technical services; the cooperation has expanded from single-market agency to a global scope.

Overseas Projects and Operations

1. SINOPEC SSC (01033.HK) disclosed on August 17 that its wholly-owned subsidiary acquired 50% equity of Mexico's DS company and a 0.01% interest in the EBANO project for USD 4 million, resulting in an indirect 55% interest in the EBANO project upon completion, with plans to make additional investment of no more than USD 212 million; the EBANO oilfield holds petroleum geological reserves of 4.92 billion barrels, and the transaction does not constitute a connected transaction or major asset restructuring.

2. MMG (01208.HK) disclosed on August 19 that one employee and one contractor employee of its Las Bambas mine in Peru died in an accident while replacing water pumps in a purification pond on August 18, with three others injured; as a precautionary measure, activities in the relevant area have been suspended and the mine has halted operations, with a gradual resumption expected from August 21.

3. MONGOLIA ENERGY (00276.HK) disclosed on August 21 that its indirect wholly-owned subsidiary MoEnCo entered into a construction contract with contractor Orgil J Trade LLC to build heating pipelines, clean water pipes and sewage pipes at the Hushuotu coal mine, for a total consideration of MNT 2.679 billion (approximately HKD 5.626 million); the pipelines connect the new office administrative area with the industrial area, supporting the relocation arrangement under the mining plan in which the current office area will be used as a spoil area.

Overseas Financing

1. INGENIC (03223.HK) launched its global offering of H shares on August 17, proposing to offer 31.2873 million H shares at a maximum offer price of HKD 102.80 per share, with the Hong Kong public offering accounting for approximately 10% and the international offering approximately 90%; at the maximum offer price, 11 cornerstone investors will subscribe for an aggregate of approximately USD 191.65 million, representing 46.74% of the offered shares. Trading of the H shares is expected to commence on the Stock Exchange on August 25.

2. ASR (688220.SH) disclosed on August 15 that its board reviewed and approved the resolution to issue H shares and list on the Main Board of the Hong Kong Stock Exchange, proposing to issue overseas listed foreign shares and apply for listing to further enhance capital strength and deepen its internationalization strategy; specific details remain subject to shareholders' meeting deliberation and regulatory filing approval.

3. XINGYU CO.,LTD (601799.SH) disclosed on August 15 that its H-share issuance received the filing acceptance notice for overseas issuance and listing from the CSRC, proposing to issue no more than 44.79965 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange, subject to the approval, endorsement or filing of the SFC and the Stock Exchange.

4. HUNAN YUNENG NEW ENERGY BATTERY MATERIAL (301358.SZ) submitted its H-share listing application to the Hong Kong Stock Exchange on August 17, with CSC International and HSBC as joint sponsors; the company focuses on phosphate cathode materials, and according to Frost & Sullivan, it has ranked first among global phosphate cathode material suppliers for six consecutive years from 2020 to 2025 by shipment volume, holding a 28.2% global market share in 2025.

Regulation and Compliance

1. HAIXI PHARMA (02637.HK) disclosed on August 17 that its self-developed innovative drug HX9428 was granted Fast Track designation by the US FDA, for development to treat neovascular age-related macular degeneration; the drug is an oral small molecule and has received FDA approval to conduct Phase II clinical trials in the United States.

2. STAIDSON BIOPHARM (300204.SZ) disclosed on August 20 that its subsidiary Jiangsu Beijietai received a formal letter from the US FDA agreeing to clinical trials of STSP-0601 (bomintafase alfa for injection) for the treatment of bleeding in patients with hemophilia A or B with inhibitors; the drug had previously obtained a drug registration certificate from the NMPA in June 2026.

3. SDKX (688136.SH) disclosed on August 18 that the imported Maibo Taike infliximab biosimilar (Leiting) received marketing approval from the Thai Food and Drug Administration; the product had previously gained market access in Peru, Indonesia, Pakistan, Bangladesh, Malaysia and other markets.

NewTimeSpace Going Global Observation

This week's going-global themes centered on two directions: biomedicine and overseas resources. In biomedicine, HENLIUS's global strategic cooperation with Sandoz, GAUSH MEDITECH's global distribution with HEIDELBERG, combined with the successive overseas regulatory access achieved by HAIXI PHARMA, STAIDSON BIOPHARM and SDKX, show Chinese pharmaceutical companies and device manufacturers moving from single-product licensing toward global commercialization networks. In resources and energy, SINOPEC SSC's acquisition of Mexican oilfield interests, MMG's push to resume production at its Peruvian mine, and MONGOLIA ENERGY's coal mine supporting infrastructure improvements reflect continued mining capital investment in overseas resource projects. On the financing side, INGENIC, ASR, XINGYU CO.,LTD and HUNAN YUNENG NEW ENERGY BATTERY MATERIAL are collectively advancing H-share issuances, with A-share companies accelerating their access to international capital markets via Hong Kong. Overall, equity mergers and acquisitions, global licensing cooperation and overseas regulatory access constitute the main forms of this week's going-global activity, with the going-global approach extending further toward capital and industrial cooperation beyond the stage dominated by product exports.

This article is for information compilation only and does not constitute any investment advice.

5100 XIZANG (01115.HK): Grants Exclusive Distribution Rights in Malaysia, Expanding into Southeast Asian and Middle East Premium Water Markets

Wed, 19 Aug 2026 14:00:28 GMT

NewTimeSpace News: On 19 August 2026, 5100 Xizang Glacier Company Limited (stock code: 01115) voluntarily announced that its wholly-owned subsidiary, Jiafuli Investment Limited, entered into a distribution contract on the same day with Landmark Holding Sdn. Bhd., a company incorporated in Malaysia, granting the distributor exclusive distribution rights for 5100 Xizang Glacier mineral water products in Malaysia and non-exclusive distribution rights for certain Southeast Asian and Middle East export markets, including Singapore, Indonesia, Qatar, the Kingdom of Saudi Arabia and the United Arab Emirates.

The distributor is the sole authorized distributor, importer and brand operator of 5100 mineral water in Malaysia, and its sales in the export markets will be conducted through its own commercial network. The group will provide the distributor with marketing support for brand promotion and market development in Malaysia, including online and offline promotional activities and event sponsorship. The initial cooperation term is three years from the date of the distribution contract, renewable automatically for another three years upon the distributor meeting certain performance targets.

The cooperation marks another milestone in the group's overseas expansion strategy and lays the foundation for entering premium drinking water markets with significant growth potential in Southeast Asia and the Middle East. The group previously voluntarily announced on 29 May 2026 that certain aquatic products had obtained halal certification in Malaysia. The group will continue to seize overseas opportunities and accelerate its international market build-out.

CHINAGOLDINTL (02099.HK): Engages SRK to Advance Independent NI 43-101 Feasibility Study for Changshanhao Underground Development, Pre-Development Works Commence

Mon, 17 Aug 2026 13:27:15 GMT

NewTimeSpace News: On 17 August 2026 (Vancouver), China Gold International Resources Corp. Ltd. (stock code: 02099) announced that it has entered into an agreement with SRK Consulting to conduct an independent feasibility study stage assessment of the proposed underground development project at the Changshanhao Gold Mine in the Inner Mongolia Autonomous Region of China, and to prepare a technical report in accordance with Canadian National Instrument NI 43-101 Standards of Disclosure for Mineral Projects.

As open-pit mining at the Changshanhao Gold Mine progressively enters the later stage of the mine life, the company is advancing the transition to underground mining, with the "block caving" method currently proposed as the primary mining method for the mineral resources beneath and adjacent to the existing pit. Engaging SRK is an important step for the company to establish an independent technical and economic basis in accordance with NI 43-101 and applicable Canadian Institute of Mining, Metallurgy and Petroleum (CIM) standards; in parallel, pre-development underground works have been independently initiated under the engineering, technical and regulatory framework applicable in China.

The proposed underground development project at the Changshanhao Mine has completed engineering design and a "preliminary design" under applicable Chinese technical standards and regulatory requirements, and construction contractors have mobilised to commence pre-development underground works, including development works such as shafts and ramps and related site infrastructure preparation. The domestic "preliminary design" is intended to satisfy domestic building engineering design, construction and regulatory requirements; it is not prepared in accordance with NI 43-101 or CIM standards and does not constitute, and should not be interpreted as, a feasibility study or technical report under NI 43-101.

SRK's work will proceed in two main stages. In the first stage, gap analysis, SRK will conduct a comprehensive review of the existing geological, engineering and technical data for the underground project and compare it with the relevant requirements of feasibility study stage assessments under NI 43-101 and CIM standards, identifying data that can be used directly, data requiring further validation or analysis, and additional technical work or data needed to support an independent NI 43-101 feasibility study stage assessment. In the second stage, following completion of the gap analysis, SRK will independently conduct the technical and economic assessments required to support the feasibility study stage and prepare the corresponding NI 43-101 technical report. The mine plan, production schedule, mine life, mineral reserve estimates and economic analysis ultimately determined under NI 43-101 will be established through SRK's independent work, and the results may differ materially from the conclusions contemplated by the existing domestic preliminary design. The company emphasises the strengthening of rock mechanics, geotechnical and hydrogeological investigation and analysis, which are particularly important for assessing the suitability of block caving and related design.

Mr. Hou Chenguang, Chairman and Chief Executive Officer of the company, stated that as the Changshanhao open-pit mine gradually enters the later stage of its mine life, advancing the development potential of Changshanhao's underground resources has become an important focus, and it is necessary to establish an independent technical and economic basis for the project in accordance with internationally recognised reporting standards; the goal is not only to advance underground development but also to ensure that the long-term mine plan is built on rigorous technical work, appropriate resource and reserve classification, and prudent assessment of the project's technical and economic feasibility. China Gold International is a gold and base metals mining company incorporated in British Columbia, Canada, operating the Changshanhao Gold Mine and the Jiama copper-gold-polymetallic mine in Tibet, and is listed on the Toronto Stock Exchange (CGG) and the Main Board of the Stock Exchange of Hong Kong (02099).

SHOUGANG CENT (00103.HK): Signs Cooperation Letter of Intent with Beauty Realm Capital, Plans Joint Venture to Expand Global Industrial Rayon Market

Mon, 17 Aug 2026 10:16:42 GMT

NewTimeSpace News: On 17 August 2026, Shougang Century Holdings Limited (stock code: 00103) announced that it had recently entered into a cooperation letter of intent with Beauty Realm Capital (Beauty Realm European M&A Fund (Phase I) Limited), pursuant to which the parties initially propose to jointly establish a joint venture, aiming to achieve complementary advantages and synergy in the tyre reinforcement materials sector and jointly expand the global industrial rayon products market. To the best of the directors' knowledge after making all reasonable enquiries, Beauty Realm Capital and its ultimate beneficial owner are third parties independent of the company and its connected persons.

Beauty Realm Capital is the controlling shareholder of Cordenka GmbH & Co. KG (Cordenka), a German company and a globally leading producer of industrial rayon, a high-performance tyre carcass reinforcement material. The group has long been dedicated to the steel cord sector and, like Cordenka, is a major supplier of tyre reinforcement materials, with highly overlapping customer bases and notable business complementarity. Upon the establishment of the joint venture, the parties will integrate product lines and customer resources to further enhance their voice and brand influence in the global tyre supply chain.

The parties are also highly aligned on sustainable development. The group continues to increase the share of super tensile (ST) and ultra tensile (UT) steel cord products, with a new generation of mega tensile (MT) products gradually being introduced to the market, and has achieved mass supply of products with a recyclable steel ratio exceeding 70%. Cordenka's industrial rayon is produced from wood pulp, with a carbon footprint lower than traditional petrochemical materials, fitting the low-carbon circularity needs of vehicle manufacturers and tyre makers. The cooperation will further promote synergistic improvement between the parties in sustainable development.

Apart from provisions relating to confidentiality, governing law, dispute resolution and legal validity, the terms of the cooperation letter of intent are not legally binding, and the proposed cooperation is subject to further negotiation and the execution of a formal agreement. As of the date of this announcement, no legally binding agreement has been entered into; should the proposed transactions be materialised, the company will publish further announcements in due course in accordance with the Listing Rules.

SINOPEC SSC (01033.HK): Wholly-Owned Subsidiary to Acquire 50% of Mexico DS for USD 4 Million, with Follow-on Investment of up to USD 212 Million

Mon, 17 Aug 2026 10:12:22 GMT

NewTimeSpace News: On 17 August 2026, Sinopec Oilfield Service Corporation (stock code: 01033) announced that its wholly-owned subsidiary, Sinopec International Petroleum Service Corporation (SIPSC), together with its Mexico subsidiary, plans to acquire the 50% equity interest in DS Servicios Petroleros, S.A. de C.V. (Mexico DS) held by DIAVAZ for USD 4 million, together with the 0.01% interest in the EBANO project held by DIAVAZ's wholly-owned subsidiary D&S Petroleum, S.A. de C.V.; following the acquisition, SIPSC will provide follow-on investment of up to USD 212 million (including abandonment costs) to the EBANO project in Mexico according to project progress and funding needs.

Mexico DS is a joint venture of the company, 50% held by SIPSC and 50% by DIAVAZ, serving as the operator of the EBANO project and responsible for crude oil production of the EBANO oilfield. Upon completion of the acquisition, SIPSC and its Mexico subsidiary will hold 99% and 1% of Mexico DS respectively, indirectly obtaining a 55% interest in the EBANO project, with Mexico DS consolidated into the company's reporting scope. The consideration will be paid in instalments, with the first payment of USD 3.4 million released at closing and the remaining USD 0.6 million retained as escrowed compensation funds to be released one year after the closing date.

The EBANO oilfield is located in the Tampico Basin of the western central Gulf of Mexico coast, covering an area of 1,569 square kilometres. Discovered in 1903, it is a fractured-porosity carbonate heavy oil reservoir. Based on existing seismic evaluation, the oilfield holds petroleum geological reserves of 4.92 billion barrels (approximately 743 million tonnes) with an overall recovery factor of 6.84%; the deeper KTS layer contains additional petroleum resources of approximately 351 million barrels (about 53 million tonnes), and the deeper Jurassic formations also offer exploration potential. As partner DIAVAZ suffered consecutive losses and was unable to invest on an equal basis, the EBANO development plan had been postponed several times; the transaction will leverage Sinopec's integrated geological-engineering advantages to optimise the company's business layout in Mexico.

The board has approved the relevant resolutions. The acquisition does not constitute a connected transaction nor a major asset restructuring; the transaction does not meet the thresholds requiring shareholders' meeting approval under the listing rules of the Shanghai and Hong Kong exchanges, but is still subject to shareholders' meeting approval under the company's internal control management system. Completion of the acquisition is subject to the satisfaction or waiver of a series of conditions precedent, including amending provisions in Mexico DS's articles of association restricting the nationality of equity transferees, obtaining approvals or permits from relevant government authorities at home and abroad, written consent from project partners and bank creditors, and shareholders' meeting approval; uncertainty remains as to whether and when these conditions will be satisfied.

WERIDE-W (00800.HK): H1 Revenue Up 73.3% to RMB 345.9 Million, Overseas Revenue Up 154.4%

Thu, 13 Aug 2026 00:23:55 GMT

NewTimeSpace News: On 12 August 2026, WeRide Inc. (stock code: 00800) announced its interim results for the six months ended 30 June 2026. Total revenue for the reporting period reached RMB 345.9 million, up 73.3% year on year; overseas revenue grew 154.4% year on year; gross profit was RMB 126.5 million, with gross margin improving from 30.6% in the same period of 2025 to 36.6%; and EBITDA was negative RMB 667.0 million, narrowing by 6.5% year on year.

In terms of operations, as of 31 July 2026, the Group's global L4 fleet comprised approximately 3,400 vehicles, of which the robotaxi fleet exceeded 1,800 vehicles. Overseas expansion continued: the Group announced with Uber a pilot programme for Spain's first commercial robotaxi service in Madrid (the fourth global joint deployment and its first entry into Europe); it is advancing robotaxi services with Uber in the Greater Zurich area of Switzerland (the fifth global and second European joint deployment); it entered its sixth European market and made its first Nordic entry through a strategic partnership with GreenMobility; it launched public operations with Grab in Punggol, Singapore; and its Middle East robotaxi fleet stood at approximately 400 vehicles, with overall services covering over 70% of core urban areas. In China, average daily orders per vehicle exceeded 21 in the second quarter of 2026, up 24% quarter on quarter, with a peak of 28 completed orders per vehicle per day, while domestic ride-hailing revenue grew approximately 140% quarter on quarter and registered users rose 35% quarter on quarter; the fully driverless robotaxi service area in Guangzhou tripled versus the end of 2025, covering Huangpu, Tianhe and Haizhu districts with 24/7 commercial operations.

Other business lines also progressed: the L2++/L3 solution WRD 3.0 shipped approximately 30,000 units in the second quarter of 2026, with over 30 vehicle models securing mass-production design wins for L2++; autonomous minibus services in Zurich began operating without front-row safety operators (a first in Europe) and, together with Renault Group, provided shuttle services at the Roland Garros French Open for the third consecutive year; and as of the date of the announcement, autonomous driving operations had expanded to over 60 cities in 13 countries globally. On the technology front, the self-developed world model WeRide GENESIS compresses millions of kilometres of road testing into days while reducing data collection and annotation costs by over 75%; the physical AI foundation model WeRide WITT saves up to 98% of token costs on comparable tasks, enabling a single GPU to process up to 10,000 minutes of vehicle operation video per day with up to 200x data processing efficiency. In June 2026, the Group announced the joint development with Farizon and Kwoon Chung Bus Holdings of robotaxis designed for right-hand-drive markets, with commercial services to first launch in Singapore and Hong Kong.

On the financials, operating expenses for the reporting period were RMB 1,001.6 million, of which R&D expenses were RMB 797.7 million; loss for the period was RMB 789.8 million, narrowing 0.2% year on year; non-IFRS adjusted loss was RMB 664.6 million; and basic and diluted loss per ordinary share was RMB 0.79. As of 30 June 2026, the Group held RMB 5,398.5 million in aggregate of cash and cash equivalents, time deposits, wealth management investments and restricted cash, with short-term bank borrowings of RMB 485.0 million. The Board does not recommend the payment of any interim dividend. During the reporting period, the Company repurchased 27,447,800 Class A ordinary shares on the Stock Exchange (aggregate consideration of HKD 542.98 million) and 4,335,433 American Depositary Shares on Nasdaq (aggregate consideration of USD 30.02 million).

HANKING GOLD (03788.HK): Mt Bundy Gold Project Mill Construction Commences, to Be the Largest Gold Mill in the Northern Territory

Wed, 12 Aug 2026 23:48:44 GMT

NewTimeSpace News: On 12 August 2026, Hanking Gold International Limited (stock code: 03788) voluntarily announced that, following the award of the EPC and EPCM contracts for the construction of the Mt Bundy gold project processing plant with an annual processing capacity of 5.5 million tonnes to two experienced Australian contractors, Delonix Solutions Projects Pty Ltd and CPC Engineering Pty Ltd, the Company held the groundbreaking ceremony for the processing plant construction on the same day, marking the project's official entry into the full construction phase.

The groundbreaking ceremony was held at Rustlers Roost, the processing plant construction site of the Mt Bundy gold project. Attendees included representatives of the Northern Territory Government, local electorate member Mr. Andrew Mackay, Chairman of the Northern Territory Environment Protection Authority Mr. Paul Vogel, Executive Director of the Northern Territory Department of Mining and Energy Mr. Alister Trier, Executive Director of the Mining Division of the Northern Territory Department of Lands, Planning and Environment Ms. Kathleen Davies, the Company's Executive Director, Chief Executive Officer and President Dr. Qiu Yumin, Chairman of the Board Mr. Xia Zhuo, Executive Directors Mr. Tang Wenbin and Ms. Zhang Jing, Chief Executive Officer of CPC Engineering Mr. Glenn Weir, Managing Director of Delonix Solutions Mr. Philippe Vatin, Australia Regional Manager of CITIC Heavy Industries Mr. David Parry, as well as over 40 other guests including government officials and industry and community representatives. Journalists from the Australian Broadcasting Corporation and News Limited also attended the ceremony.

At the ceremony, Mr. Andrew Mackay, Member of the Northern Territory Parliament, spoke on behalf of the Northern Territory Government, highly commending Hanking Gold's persistence and efforts on the project over the past 12 years. He noted that the processing plant under construction will be the largest gold mill in the Northern Territory and, once completed and operational, will become the second-largest gold mine by annual output in the Territory, and that the Northern Territory Government will continue to support the Company's development. Dr. Qiu stated that the Company invested in Primary Gold, then an Australian listed company, in 2014, fully acquired Primary Gold in 2018 and delisted it, after which gold reserves increased by more than tenfold. Representatives of the main EPC and EPCM contractors also committed to building and commissioning the gold processing plant on time, to quality and within budget. Site levelling works for the Mt Bundy gold project have been substantially completed, and the processing plant construction has officially entered the full construction phase.

The United Laboratories International (03933.HK): UBT48128 Tablets Obtain US FDA Clinical Trial Approval

Tue, 11 Aug 2026 10:25:40 GMT

NewTimeSpace News: On 11 August 2026, The United Laboratories International (03933.HK) announced that UBT48128 Tablets, a Class 1 innovative drug self-developed by its wholly-owned subsidiary United Biotech, has received Investigational New Drug (IND) approval from the US FDA.

According to the announcement, UBT48128 is a small-molecule GLP‑1 receptor agonist. It works by stimulating insulin secretion, suppressing appetite and regulating energy metabolism to lower blood glucose and induce weight loss.

Frost & Sullivan and LeadLeo Release Landmark 2026 AI Agent Report; YouLianCloud Named Among the Chinese Agents with the Greatest Global Development Potential

Tue, 11 Aug 2026 05:41:43 GMT

On August 5, Frost & Sullivan, together with LeadLeo, released the report 2026 Best Application Practices of AI Agents in China (hereinafter referred to as "the Report") at the "Advancement and Leap of AI" sub-forum of the GIL 2026 summit. The Report projects that China's AI Agent market will grow from RMB 2.6 trillion in 2025 to RMB 20.1 trillion in 2030, representing a compound annual growth rate of 50.4% over 2025–2030. The B-side (enterprise market) is the principal variable driving market growth, contributing approximately 90% of revenue over the long term.

The Report defines an AI Agent as an intelligent system that takes a large model as its core cognitive engine and autonomously perceives, remembers, decides, interacts, and executes without continuous human intervention. The Report points out that current product innovation concentrates on four directions: the disappearing of interaction interfaces, multi-agent collaboration, deep cultivation of vertical scenarios, and lightweight architecture. Business models, meanwhile, will evolve within one to three years from single process-based charging to a dynamic hybrid model—where process-based charging secures baseline revenue and outcome-based charging is tied to business value.

In terms of evaluation mechanism, the Report adopts a four-dimensional framework covering market demand, implementation value, commercial capability, and product innovation. An expert jury composed of industry researchers, consulting teams, and industry professionals including the Frost & Sullivan expert committee conducted the selection through four stages: content submission, evaluation and research, expert assessment, and results announcement. The process ultimately produced TOP10 lists in five categories: the Most Popular Agents, the Chinese Agents with the Greatest Global Development Potential, the Most Practical Agents, the Most Innovative Agents, and the Agents with the Greatest Commercial Value Potential. Selected entries are listed in no particular order, sorted by the pinyin initials of company names.

Among these, the "Chinese Agents with the Greatest Global Development Potential" category emphasizes products' overseas expansion capability, global adaptability, and international market presence, and requires selected products to possess a broad network of international partners and the ability to attract overseas investment or gain recognition from international institutions. The Report's structural analysis of this list shows that platform-type products account for 50%, the ToB business model for 60%, and vertical scenarios for 60%. The Report interprets this as follows: the overseas advantages of Chinese Agents mainly derive from accumulated industry experience and business process know-how; scenarios such as content creation, marketing, finance, and intelligent vehicles feature well-defined deliverables and clear procurement standards, making replicable internationalization paths easier to establish.

Among the ten products ultimately selected for this list, the YouLianCloud Qilin Financial LLM is the only product focused on the financial vertical. The Report positions it as an "enterprise-grade financial Agent platform," with the stated selection reason being "its financial vertical-domain scenarios and exploration of cross-border AI." Regarding domestic market application, the Report notes on the international recognition dimension: YouLianCloud has industry accumulation and customer validation in the field of financial AI application, and its professionalism has been recognized. Regarding overseas market application, the Report notes on the overseas implementation dimension: the product meets scenario-level adaptation requirements for overseas markets and is exploring the overseas expansion of financial AI applications; and on the global adaptability dimension: the vertical financial large model is paired with an Agent framework, adapting to multilingual and local compliance needs. The Report also tags the product with five characteristic labels: "finance-native," "financial large model," "multilingual adaptation," "cross-border cloud architecture," and "fintech going global."

The other products selected for the same list are Alibaba Cloud Qoder, the Baidu Yijing All-Scenario Digital Human Platform, Manus, StepFun Step-GUI, Kuaishou's Kling AI, Marketingforce's Tforce Marketing LLM, MiniMax Agent, the SenseTime Intelligent Cockpit, and Tencent Cloud's Agent Development Platform (ADP). In terms of list composition, tracks such as programming, content creation, digital human marketing, and intelligent terminals all have representative products selected, while the finance direction is occupied by YouLianCloud.

From the Report's selection logic, it can be seen that the market application of YouLianCloud's product technology presents two dimensions, domestic and international: inward, it builds professional recognition on the strength of industry accumulation and customer validation in financial AI application; outward, with multilingual adaptation, local compliance, and a cross-border cloud architecture, it explores the overseas expansion of financial AI applications.

(This article is a paraphrase of the report 2026 Best Application Practices of AI Agents in China, jointly published by Frost & Sullivan and LeadLeo. All data and evaluations are quoted from the original report.)

HANKING GOLD (03788.HK): EPC and EPCM contracts for 5.5 Mtpa processing plant of Mt Bundy gold project awarded to two contractors, with aggregate contract value of approximately AUD 120.98 million

Tue, 11 Aug 2026 00:23:14 GMT

NewTimeSpace News: On 10 August 2026, Hanking Gold International Limited (stock code: 03788) published a discloseable transaction announcement, announcing that, following a competitive tendering process and full plant evaluation, Primary Gold Pty Ltd, a wholly-owned subsidiary of the Company (as project owner and operating entity), awarded the two contracts for the construction of the 5.5 million tonnes per annum (Mtpa) processing plant of the Mt Bundy gold project to two key delivery contractors after trading hours on that day: Delonix Solutions Projects Pty Ltd was awarded the CO02 contract (the "EPC Contract") for engineering, procurement and construction of the Mt Bundy dry processing plant (SP1 package); and CPC Engineering Pty Ltd was awarded the CO01 contract (the "EPCM Contract") for engineering, procurement and construction management of the Mt Bundy wet processing plant (SP2 package). The aggregate contract value under the EPC Contract and the EPCM Contract is approximately AUD 120.98 million.

The EPC Contract (dry plant SP1), undertaken by Delonix Solutions, covers the complete design, engineering, procurement, construction, installation and commissioning of the dry plant, including the ROM bin and primary crushing circuit, secondary crushing, closed-circuit HPGR tertiary crushing circuit, covered fine ore stockpile and reclaim, civil, structural, mechanical, piping, electrical, process control and fire protection works, with a contract value of AUD 92.48 million on a fixed price basis; the dry plant has a maximum design processing capacity of 7.0 Mtpa, higher than the nameplate capacity of 5.5 Mtpa, with built-in capacity reserved for future expansion, targeting completion and commissioning of the dry plant by December 2027. The EPCM Contract (wet plant SP2), undertaken by CPC Engineering, covers the engineering from fine ore stockpile reclaim to the wet plant and from Tom's Gully fine ore bin reclaim feeding to the wet plant, with CPC Engineering managing all procurement for SP2 on behalf of Primary Gold and responsible for interface management with the dry plant EPC Contract; the EPCM budget is AUD 28.5 million (including a 15% contingency), targeting completion of the works by April 2027 and commissioning of the wet plant in early 2028 to support first gold production in Q1 2028.

The delivery model intentionally separates the dry plant, suited to fixed-price modular EPC, from the wet plant, which adopts an EPCM model with fixed-price engineering and procurement, enabling the Company to directly and clearly control major equipment procurement while retaining scheduling flexibility. The announcement disclosed that, notwithstanding the significantly optimised process flows and the newly added future expansion option, the awarded contract values and the remaining plant capital estimates remain consistent with the final feasibility study, with plant capital expenditure of approximately AUD 393.97 million; the plant construction and subsequent mining operations will create up to 400 jobs. Delonix Solutions is a Perth-based mineral processing engineering company (established in 2011), and CPC Engineering is an engineering group in Western Australia with over 50 years of operating history; both companies and their ultimate beneficial owners are third parties independent of the Company and its connected persons. Dr. Qiu Yumin, executive director, chief executive officer and president of the Company, commented that awarding the EPC and EPCM contracts for the plant construction is an important step in developing the Mt Bundy gold project into a producing gold mine, and that with the ball mill already ordered, the construction site cleared and earthworks progressing, the project remains on track to commence gold production in Q1 2028.

CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval

Mon, 10 Aug 2026 11:08:02 GMT

NewTimeSpace News: On 10 August 2026, CSPC Pharmaceutical Group (01093.HK) announced that SYS6037 Injection (monkeypox mRNA vaccine), a Class 1 new prophylactic biological product co‑developed by the Group and the Institute of Microbiology, Chinese Academy of Sciences, has obtained approval from the US FDA to carry out clinical trials.

According to the announcement, the product is a multi‑antigen monkeypox vaccine encoded by a single mRNA strand for the prevention of monkeypox. It adopts a concise technical route, which is conducive to quality control and reduction of production costs.

MINTH GROUP (00425.HK): Groundbreaking ceremony held for new production plant in Alabama, US; planned phased investment of approximately USD 430 million

Fri, 07 Aug 2026 01:01:48 GMT

NewTimeSpace News: Minth Group Limited (stock code: 00425) published a voluntary announcement, announcing that on 3 August 2026 the Group, together with the City of Gadsden, held a groundbreaking ceremony for the Group's new production plant in Gadsden, Alabama, United States. The plant will be developed on a site of approximately 400 acres formerly occupied by Republic Steel and Gulf States Steel, with the Group expecting to invest a total of approximately USD 430 million in phases; upon completion and full operation, it is expected to create more than 1,300 jobs and become the Group's largest plant site globally.

The first-phase capacity of the project is expected to commence production in 2027. Since acquiring the site in March 2026, the Group has advanced the site preparation and redevelopment works and has initiated highly vertically integrated capacity planning and feasibility analysis covering its four product lines of body structural, plastic, aluminium and metal and trim products. The Group principally operates two major businesses of automotive components and tooling, and is developing a second growth curve in new areas including artificial intelligence, robotics, low-altitude economy and intelligent mobility.

The Board considers that the project will strengthen the Group's manufacturing presence in North America and enhance its localised production and service capabilities; the estimated investment amount, construction timeline, expected production commencement and job figures are based on the Group's current plans and estimates and may change due to factors including construction progress, market conditions and regulatory approvals.

Wai Chun Bio-Technology (00660.HK): Appointed Exclusive Overseas General Agent for China's Leading Crane Manufacturer; Three-Year Agreement

Wed, 05 Aug 2026 23:56:29 GMT

NewTimeSpace News: Wai Chun Bio-Technology Limited (stock code: 660) announced that on 5 August 2026, it signed an Exclusive Overseas General Agency Agreement with Henan Mine Crane Co., Ltd., under which the company was appointed as the exclusive overseas general agent for crane and mining equipment products globally (excluding mainland China).

The agreement term is three years from 5 August 2026 to 5 August 2029, with priority renewal rights under equivalent conditions. The authorized products include "Kuangyuan" brand bridge cranes, gantry cranes, electric hoists and related mining equipment. The licensor, a leading Chinese crane manufacturer with annual revenue of approximately RMB 6.5 billion, will provide competitive "authorized agency floor prices"; the company has the right to independently determine final sales prices, with all sales premiums belonging to the company.

Kinetic Development (01277.HK): South Africa Makhado Project Commences Production on 1 August; 280kt Coking Coal Expected in 2026

Wed, 05 Aug 2026 00:51:58 GMT

NewTimeSpace News: Kinetic Development Group Limited (stock code: 1277) announced that its flagship Makhado coking coal project in South Africa's Limpopo province officially commenced production on 1 August 2026. The open-cast mine covers 7,651.28 hectares with resources of 706 million tonnes, producing premium low-sulphur high-CSR coking coal as its main product and 5,500 kcal low-sulphur thermal coal as secondary product. The coal washing plant has passed commissioning and met quality specifications.

The group expects to produce 280,000 tonnes of coking coal and 230,000 tonnes of thermal coal in 2026, rising to 880,000 and 720,000 tonnes respectively in 2027, with further expansion to 2.2 million and 1.8 million tonnes within two years. Over 40 overseas potential customers have been developed, primarily in Vietnam, Indonesia, and India.

HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China

Tue, 04 Aug 2026 09:32:21 GMT

NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) released a voluntary announcement on 4 August 2026. The US Phase II clinical trial application for HX9428, the Company’s in‑house‑developed innovative drug for neovascular age‑related macular degeneration (nAMD, wet AMD), has been approved by the FDA. In parallel, the second randomized, positive‑control (head‑to‑head versus aflibercept) Phase II study (CTR20262884) has been formally initiated in China, planning to enrol 60 subjects.

HX9428 is an oral investigational innovative drug. It aims to overcome the limitation that current nAMD therapies mainly rely on intravitreal injection, by delivering a convenient administration regimen and improving patients’ long‑term treatment compliance. Phase I and Phase II dose‑expansion studies have been completed previously. The Company commented that the US Phase II clearance together with the launch of the Chinese controlled study mark important progress in global clinical development. HX9428 has not yet been approved for marketing; its safety and efficacy require further verification.

Chery Automobile (09973.HK): July 2026 Sales Reach 261,876 Units Across Five Brands, Up 24.1% YoY; NEV Sales at 119,441 Units

Sun, 02 Aug 2026 12:01:57 GMT

NewTimeSpace News: Chery Automobile Co., Ltd. (stock code: 9973) announced that the group's total sales across its five brands in July 2026 reached 261,876 vehicles, representing a year-on-year increase of 24.1% from 211,066 units in the same period last year.

According to the announcement, by brand: Chery brand sold 183,615 units (up 28.0% YoY), with cumulative sales of 1,102,029 units year-to-date (up 25.7% YoY); Exeed brand sold 8,376 units (up 0.6% YoY), with YTD sales of 41,564 units (down 39.3% YoY); Jetour brand sold 50,108 units (up 1.3% YoY), with YTD sales of 308,845 units (down 11.5% YoY); iCAR brand sold 9,068 units (up 38.1% YoY), with YTD sales of 54,460 units (up 6.6% YoY); and Luxeed brand sold 10,709 units (up 227.7% YoY), with YTD sales of 30,054 units (down 37.6% YoY).

The announcement disclosed that new energy vehicle sales in July 2026 reached 119,441 units, while export sales reached 196,311 units. For the first seven months of 2026, cumulative sales across the five brands totaled 1,536,952 units, up 10.3% from 1,393,462 units in the same period last year. The announcement noted that all figures disclosed are unaudited and have not been confirmed by the company's auditor, and may be subject to adjustment and final confirmation.

CWT International (00521.HK): Joint Venture Established for Redevelopment of Singapore Property with Total Capital Contribution of Approximately SGD 51.75 Million

Fri, 31 Jul 2026 00:40:11 GMT

NewTimeSpace News: On 30 July 2026, CWT International (00521.HK) issued an announcement stating that CWT Pte., its wholly-owned subsidiary, has signed a joint venture agreement with HPC Realty and other joint venture partners to jointly invest in the redevelopment project of a property located in Tuas, Singapore.

As disclosed in the announcement, the joint venture company has secured external financing of up to approximately SGD 490 million. CWT Pte. will hold a 19% stake. Its total planned capital contribution of SGD 51.75 million (including an initial contribution of SGD 15.29 million and subsequent follow-on contributions) will be funded by the Group’s internal resources. CWT International stated that the project will sustain the Group’s warehousing footprint and capture opportunities arising from the westward relocation of Singapore’s port. Investors are reminded to exercise caution.

Chifeng Jilong Gold Mining Group (06693.HK): Significant Resource Update for Sepan SND Project of Vientiane Mining in Laos, Total Gold Equivalent Metal Volume Reaches 260 Tonnes

Thu, 30 Jul 2026 23:40:11 GMT

NewTimeSpace News: On 30 July 2026, Chifeng Jilong Gold Mining Group (06693.HK) released an announcement regarding the updated mineral resource estimate of the SND project prepared in accordance with the JORC Code. The total ore tonnage amounts to 360 million tonnes, with combined measured and indicated total metal volume hitting 260 tonnes gold equivalent, a rise of around 143% from the first release.

Chifeng Jilong Gold Mining Group stated that Snowden Optiro has conducted an independent review of this resource estimate. Preliminary mineral processing test results demonstrate the ore is amenable to easy separation, delivering an overall gold recovery rate of approximately 88% and an overall copper recovery rate of roughly 88.5%. The ore body remains open to the southwest and at depth, leaving room for further expansion of resource scale.

HSBC Holdings plc (00005.HK): Disposal of Australian Residential and Personal Loan Portfolio for A$36 Billion

Thu, 30 Jul 2026 23:21:06 GMT

NewTimeSpace News: On 31 July 2026, HSBC Holdings plc (00005.HK) issued an announcement. HSBC Bank Australia, the Group’s indirect wholly-owned subsidiary, entered into an asset purchase agreement with an entity under a Blackstone affiliate fund to dispose of its Australian residential and personal loan portfolio with a total book value of roughly A$36 billion, and the transaction will be settled in cash upon completion.

HSBC Holdings stated that the disposal is expected to result in a loss of less than US$100 million. The remaining segments of its Australian retail banking business will be wound down gradually within 18 months, while corporate, institutional banking and other businesses will be consolidated into HSBC’s Sydney branch. Restructuring costs of around US$300 million are anticipated.

ASCOTT: Secures 9 Projects in Vietnam in H1 2026, Adding Over 3,200 Units

Thu, 30 Jul 2026 08:14:44 GMT

NewTimeSpace News: On 30 July 2026, ASCOTT released an announcement stating that the Group signed nine property management agreements across Vietnam in H1 2026, covering more than 3,200 units in aggregate. Four of these projects were sealed with long-term partner Sun Group, while the remaining five were secured with new property owners.

These new additions grow ASCOTT’s Vietnam portfolio by over 30%, with a total of around 12,000 units spanning 14 Vietnamese cities.

According to the announcement, ASCOTT currently operates 16 properties in Vietnam, with major upcoming launches including Ascott Tay Ho Hanoi and Harris Resort Cam Ranh set to open progressively in the pipeline.

CIMIC Group: UGL Secures Stage 2 Contract for Neoen’s Goyder Battery Energy Storage Project in South Australia

Thu, 30 Jul 2026 08:03:34 GMT

NewTimeSpace News: On 30 July 2026, CIMIC Group released an announcement confirming that its subsidiary UGL has been appointed by Neoen and Tesla to deliver Stage 2 of the Goyder Battery Energy Storage Project.

As stated in the announcement, Stage 2 will add 227MW/907MWh of energy storage capacity. Combined with the ongoing Stage 1 construction work undertaken by UGL, the total project capacity will reach 454MW/1814MWh. UGL will deliver the balance of plant works, including civil, electrical and high-voltage infrastructure installation, as well as testing and commissioning for the balance of plant facilities.

Construction of Stage 2 is scheduled to commence in August 2026, with commercial operation targeted for 2028.

CONCORD HC GP(02453.HK) Signs Cooperation Agreement with Ministry of Health of Uzbekistan to Jointly Build and Operate Gamma Knife Radiosurgery Centre

Wed, 29 Jul 2026 08:49:08 GMT

NewTimeSpace News: On 29 July 2026, Concord Healthcare Group Co., Ltd. (02453.HK) released a voluntary announcement. The Group entered into a key cooperation agreement with the Ministry of Health of the Republic of Uzbekistan on 29 July 2026, to construct and operate a Gamma Knife Radiosurgery Centre at the Tashkent National Medical Centre. Adopting the PPP model, the Company will provide full investment and undertake operation. The cooperation lasts for 15 years, with project revenue shared by both parties.

Drawing on its proven expertise in tumour radiotherapy, Gamma Knife centre operation and high-end medical equipment management, the Company complements the Ministry of Health’s strengths in medical premises, medical insurance system and local healthcare resources. According to the Group, this cooperation constitutes a vital milestone in its international expansion into Central Asia. It enables asset-light technology export, creates synergies with the proton therapy business at its Guangzhou hospital, establishes a cross-border multi-disciplinary consultation and patient referral system, and delivers a new stable overseas revenue stream. Both sides plan to deepen collaboration in radiotherapy centres, imaging diagnostic centres and AI applications in the future.

iWOW Technology Completes Approximately SGD 15 Million Placement to Accelerate Expansion of AgeTech and Clinical Nutrition Businesses

Wed, 29 Jul 2026 08:00:16 GMT

NewTimeSpace News: On 28 July 2026, iWOW Technology issued an announcement stating that it had completed the placement of 66,667,000 new ordinary shares at a placement price of SGD 0.225 per share. The gross fundraising proceeds totalled roughly SGD 15 million, while net proceeds after deducting relevant expenses stood at about SGD 14.5 million. The placed shares account for approximately 18.8% of the enlarged issued share capital, and are expected to be listed on Catalist with effect from 9 a.m. on 30 July.

iWOW stated that the net proceeds raised will be utilised for expanding the production capacity of its clinical nutrition business (GentleFoods), international expansion including pilot deployments in the United States and Japan, research and development, sales and marketing activities, settlement of the consideration payable for the acquisition of The Gentle Group and post-acquisition integration, as well as general working capital.

IPS Securex Holdings: Awarded SGD 1 Million Contract for Data Centre Security Systems

Wed, 29 Jul 2026 07:54:48 GMT

NewTimeSpace News: On 28 July 2026, IPS Securex Holdings issued an announcement stating that its wholly-owned subsidiary Securex GS secured a contract worth around SGD 1 million to supply installation, testing, commissioning and maintenance services for access control and video surveillance management systems at a data centre.

As disclosed in the announcement, the Company’s directors and major shareholders hold no direct or indirect interests in the contract other than their respective shareholdings in the Group.

Keppel REIT to Sell Tokyo KR Ginza II Asset for Approximately JPY 11.52 Billion at a 9.7% Premium

Wed, 29 Jul 2026 07:49:29 GMT

NewTimeSpace News: On 29 July 2026, Keppel REIT released an announcement confirming it has sealed a deal to offload its 98.47% stake in Tokyo KR Ginza II at a consideration of about JPY 11.52 billion. The residual 1.53% interest will be sold simultaneously by Keppel Japan K.K.

Per the announcement, the asset is an 8-storey freehold office building fitted with retail premises on the ground floor, boasting a total leasable area of around 3,594 square metres. The transaction price carries a 9.7% premium relative to the independent valuation of JPY 10.5 billion derived via the income capitalisation approach as of 10 July 2026.

Home Control (01747.HK): Signs Strategic Cooperation MOU with Articura on Indonesia Localized Healthcare AI

Sun, 26 Jul 2026 23:32:03 GMT

NewTimeSpace News: On July 27, 2026, Home Control (01747.HK) released an announcement stating that its wholly-owned subsidiary has signed a strategic cooperation MOU with Articura. The parties plan to explore collaboration on Indonesia-localized healthcare AI infrastructure and digital health sectors, covering AI inference rule systems, clinical data governance, home remote monitoring, deployment of hospital AI applications and other areas. They will also discuss expanding business from Indonesia to other ASEAN markets.

According to the announcement, Articura is an Indonesia-based local healthcare AI company and is independent of the Company and its connected persons.

EUROEYES (01846.HK): Completes Acquisition of Dutch Refractive Surgery Group at Consideration of Approximately EUR131 Million; Reallocates Proceeds to Prioritise European Expansion

Thu, 23 Jul 2026 00:06:10 GMT

NewTimeSpace News: On 22 July 2026, EUROEYES (01846.HK) issued an announcement regarding completion of a very substantial acquisition and connected transaction, together with the variation of use of proceeds.

In respect of the acquisition: all conditions precedent under the sale and purchase agreement and subscription agreement have been satisfied, and the acquisition was closed on 22 July 2026. The aggregate consideration amounts to EUR131 million, comprising fixed equity consideration of EUR132 million, lock-box compensation of EUR14.237 million, less an adjustment for leakage of EUR14.653 million. Following completion of the subscription, EuroEyes Netherlands is owned as to approximately 90.31% by the Company and 9.69% by Manco. Nine surgeons exercised the reinvestment opportunity with a total investment of EUR2.075 million.

Regarding variation of use of proceeds: as at the date of the announcement, unused net proceeds stood at approximately HK$217 million. The Board resolved to reallocate unused funds originally designated for establishing clinics in major Chinese cities (HK$66 million) and boosting marketing activities (HK$86.49 million), amounting to around HK$152 million, to finance acquisitions of European clinic groups. The change is attributable to material shifts in China’s operating and macroeconomic environment. By contrast, the acquisition of the leading Dutch refractive surgery provider represents a highly attractive strategic opportunity — the target delivered a revenue CAGR exceeding 30% over the three years ended end-2025.

Observations on HKIC's 2025 Annual Report: Building a Comprehensive RISC-V Ecosystem and Paving the "Belt and Road" Route for Global Expansion

Wed, 22 Jul 2026 02:25:51 GMT

On July 16, 2026, the Hong Kong Investment Corporation Limited ("HKIC") released its2025 Annual Report. The report reveals that for the full year ended December 31, 2025, the corporation achieved an investment income of HKD 6.459 billion, representing a 175% year-over-year growth, and an operating profit of HKD 6.320 billion, up 181% year-over-year. The net internal rate of return (IRR) of the investment portfolio reached 14%. As of the end of June 2026, HKIC had accumulated over 200 investment projects, with every HKD 1 invested leveraging more than HKD 8 in long-term market capital co-investment.

Clara Chan, Chief Executive Officer of HKIC, noted that HKIC's investment principles and practices are progressively transitioning from capital investment to a new stage of industrial empowerment, ecosystem building, and strategic leadership. This upgrade is explicitly reflected in the annual report.

Building a Comprehensive RISC-V Ecosystem to Actively Support National Technological Innovation

As an open standard architecture based on a reduced instruction set, RISC-V is fundamentally reshaping the paradigm of chip design. With higher flexibility and cost-effectiveness, it is driving broader applications ranging from smartwatches and fitness trackers to edge computing. As the associated ecosystem matures, RISC-V is propelling the globe toward a new era of connectivity.

HKIC's investments not only accelerate the commercialization of chips but also deepen the collaboration among industry, academia, and capital. By driving an integrated ecosystem, HKIC actively assists the nation in achieving scientific and technological self-reliance while consolidating Hong Kong's position as a leading hub for open-source chip R&D, talent cultivation, and technological application.

Through strategic investments and partnerships, HKIC actively promotes the R&D and industrial application of RISC-V technology. This includes supporting StarFive in developing "Lion Rock," the world's first RISC-V architecture data center management chip engineered in Hong Kong, and backing SpacemiT in launching "K3," the world's first mass-produced RISC-V artificial intelligence CPU compliant with the RVA23 standard, which natively supports FP8 inference operations. These collaborations embody HKIC's strategy of establishing a full-chain ecosystem covering chip design, packaging and testing, and scenario applications.

As an enterprise member of the RISC-V Working Committee of the China Electronics Standardization Association and a founding member of the Hong Kong RISC-V Alliance, HKIC will continue to exert its strategic influence. It aims to anchor relevant technologies in Hong Kong, transcend geographical and industrial boundaries, and bridge the mainland's deep industrial foundation with global market opportunities.

Paving the "Belt and Road" Expansion Route to Connect National Strategy with Global Innovation

The "Belt and Road" (B&R) markets harbor immense developmental potential, which perfectly complements Hong Kong's advantages in finance, quality control, rigorous standards, and commercial innovation. HKIC translates this advantage into action, providing long-term support to enterprises and assisting them in advancing cross-border projects across B&R markets to ensure robust operations at every stage.

Through strategic partnerships, HKIC connects its portfolio companies with capital and industrial collaborations in B&R markets, establishing viable execution pathways. Three representative cases illustrate this: supporting Spark EV in exporting Hong Kong's smart mobility technology to Thailand, partnering with Bangchak Corporation to build over 1,000 EV charging stations within five years, and expanding further into Malaysia and other Southeast Asian markets; supporting SoySource in developing new drought- and salt-tolerant soybean varieties, which have already been harvested in multiple mainland cities and are undergoing trial programs in Malaysia, Thailand, and Egypt; and backing RushOwl in collaborating with the Brunei government to launch an on-demand public transportation system, driving the local digital transformation of transit.

The power of patient capital lies in active companionship. HKIC proactively connects portfolio companies with reliable business partners and upholds rigorous responsibility during the technological deployment process in B&R markets, thereby empowering Hong Kong to create sustained and profound global impact.

GDS Global Secures New Contracts Worth Approximately S$6 Million in Singapore

Tue, 21 Jul 2026 07:41:05 GMT

NewTimeSpace News: On 20 July 2026, GDS Global released an announcement, disclosing that it has recently secured a number of new contracts in Singapore valued at an aggregate of roughly S$6 million.

The announcement noted that the contracts primarily cover the supply and installation of the Group’s high-performance heat-insulated fire-resistant roller shutter systems and other roller shutter solutions. Customised designs are provided to meet clients’ operational, safety and regulatory standards. The business serves a wide range of sectors including public infrastructure, medical facilities, educational institutions and industrial premises. The above contracts are expected to be fulfilled in phases within the next two years in accordance with the timeline of each individual project.

FRASERS CENTREPOINT TRUST: Consortium Wins Tender for Mixed-Use Site at Bayshore Drive; Retail Mall Development Cost Estimated at S$613 Million

Tue, 21 Jul 2026 07:34:35 GMT

NewTimeSpace News: On 20 July 2026, FRASERS CENTREPOINT TRUST released an announcement stating that its consortium secured the tender for the mixed-use development site at Bayshore Drive with a bid of S$2.1 billion. The site carries a 99-year lease term and features a commercial floor area of roughly 22,500 square metres. The trust holds a 50% stake in the retail mall via SPT (Retail) and will oversee its development.

According to the announcement, the total development cost of the retail mall stands at approximately S$613 million, with an estimated yield on cost of about 5%. Completion is targeted for the end of 2030.

HS Optimus Holdings Completes Acquisition of 30% Stake in Medicorp Sdn Bhd

Tue, 21 Jul 2026 07:09:50 GMT

NewTimeSpace News: On 20 July 2026, HS Optimus Holdings issued an announcement stating that all preconditions under the sale and purchase agreement for the acquisition of a 30% stake in Medicorp Sdn Bhd have been satisfied in accordance with the terms of the agreement, and the acquisition was finalised on 20 July.

Upon completion, the Company allotted and issued 185,185,185 consideration shares to the vendor. The Company’s issued shares (excluding treasury shares) rose from 5,380,556,316 to 5,565,741,501, with the consideration shares accounting for approximately 3.32% of the enlarged share capital.

i-CABLE Communications (01097.HK): Invests US$4.5 Million in Korean Music Festival

Fri, 17 Jul 2026 13:46:10 GMT

NewTimeSpace News: On 17 July 2026, i-CABLE Communications (01097.HK) issued an announcement stating that PHL, its indirectly wholly-owned subsidiary, signed an investment agreement with OPG HK, OPG US, OPG KR and individual guarantors. It will invest US$4.5 million (roughly HK$35.1 million) in the Electric Daisy Carnival Korea hosted by OPG Group, with the investment sum payable in three instalments.

PHL is granted exclusive rights to conduct on-site artist exclusive interviews and produce exclusive edited content for distribution via its OTT platform and free television channels, as well as priority negotiation rights for event merchandise, brand partnerships and licensing matters.

Xiamen Jihong (02603.HK) to Place New H-shares Under General Mandate, 80% of Proceeds for Global Business Expansion

Thu, 16 Jul 2026 00:09:08 GMT

NewTimeSpace News: Xiamen Jihong Co., Ltd. (02603.HK) announced on July 16 that on July 16, 2026 (before trading hours on the Hong Kong Stock Exchange), the Company entered into a placing agreement with the placing agents, pursuant to which the Company has agreed to appoint the placing agents, and the placing agents (on an individual basis) have conditionally agreed to act as the Company's placing agents on a best-efforts basis to procure not less than six placees (who together with their respective ultimate beneficial owners will be independent third parties) to subscribe for an aggregate of up to 9,371,500 placing shares at the placing price of HK$12.24 per placing share.

The parties to the Placing Agreement are the Company and the placing agents. To the best of the Directors' knowledge, information and belief, the placing agents and their respective ultimate beneficial owners are all independent third parties. The placing agents are Guotai Junan Securities (Hong Kong) Limited, China Merchants Securities (Hong Kong) Co., Limited and Lico Securities Limited.

Assuming the Placing Shares are fully placed, the Placing Shares represent approximately 13.80% of the existing H-shares in issue (excluding treasury shares) and approximately 2.14% of the existing total issued shares (excluding treasury shares) as of the date of the announcement, and approximately 12.13% of the H-shares in issue (excluding treasury shares) and approximately 2.09% of the total issued shares (excluding treasury shares) as enlarged by the allotment and issue of the Placing Shares (assuming no change in the issued share capital of the Company from the date of the announcement up to completion). The aggregate nominal value of the Placing Shares is RMB9,371,500, calculated at par value of RMB1.00 per Placing Share.

The placing price of HK$12.24 per Placing Share represents a discount of approximately 17.02% to the closing price of HK$14.75 per H-share as quoted on the Hong Kong Stock Exchange on the last trading day; and a discount of approximately 16.68% to the average closing price of approximately HK$14.69 per H-share as quoted on the Hong Kong Stock Exchange for the last five consecutive trading days immediately preceding the last trading day. The placing price excludes applicable brokerage commissions, trading fees, transaction fees and levies. The net placing price (after deducting all applicable fees, costs and expenses) is approximately HK$12.04 per Placing Share. The placing price was determined after fair negotiation between the Company and the placing agents with reference to the prevailing market price of the H-shares. The Directors consider that the placing price is fair and reasonable and in the interests of the Company and shareholders as a whole.

Assuming the Placing Shares are fully placed, the gross proceeds from the Placing will be approximately HK$114.7 million, and the estimated net proceeds from the Placing (after deducting all fees, costs and expenses incurred by the Company in connection with the Placing (including commissions and levies)) will be approximately HK$112.8 million.

The Placing Shares will be allotted and issued under the general mandate, pursuant to which the Board is authorized to allot, issue and deal with H-shares not exceeding 20% of the H-shares in issue on the date of the relevant resolution approving the authorization passed at the extraordinary general meeting held on May 14, 2026, being 13,582,000 H-shares. As of the date of the announcement, the Company has not issued any new H-shares under the general mandate. Therefore, the general mandate is sufficient for the allotment and issue of the Placing Shares, and the Placing is not subject to further shareholders' approval.

Completion is conditional upon the fulfillment of the conditions set out in the Placing Agreement, including: approval by the listing committee for the listing and dealing of the Placing Shares on the Hong Kong Stock Exchange; obtaining all necessary approvals and permits from relevant PRC regulatory authorities in connection with the Placing; the placing agents having received the final or substantially final draft of the CSRC filing and the PRC legal opinion issued by the Company's PRC legal counsel on the CSRC filing at the completion date; the placing agents having received the PRC legal opinion issued by the placing agents' PRC legal counsel on the CSRC filing at the completion date; no material adverse change having occurred prior to completion; the representations and warranties made by the Company under the Placing Agreement being true and accurate as of the date of the Placing Agreement and the completion date; and the Company having complied with all agreements and undertakings and fulfilled all conditions to be complied with or fulfilled by it under the Placing Agreement on or before the completion date. The completion date is July 23, 2026, or such other date as the placing agents and the Company may agree in writing. If any condition is not fulfilled or waived in writing on or before 8:00 a.m. (Hong Kong time) on the fifteenth business day after the date of the Placing Agreement, each placing agent may in its sole discretion immediately terminate the Placing Agreement.

Without the prior written consent of the placing agents, during the period from the date of the Placing Agreement to the date falling 45 days after the completion date, the Company shall not directly or indirectly: effect, arrange or procure any placing, allotment, issue or transfer from treasury of any equity securities of the Company; offer to allot, issue or transfer from treasury; grant any options, rights or warrants to subscribe for such securities; or enter into any transaction with the same economic effect; or publicly announce any intention to do so. The above restrictions do not apply to the issue of Placing Shares under the Placing Agreement or the grant of awards or options under the Company's adopted share schemes. Without the prior written consent of the placing agents, the Company shall not, and shall procure that its subsidiaries shall not, directly or indirectly purchase any shares of the Company during the period from the date of the Placing Agreement to the date falling 45 days after the completion date.

The net proceeds from the Placing are intended to be used as follows: 80% or approximately HK$90.2 million for advancing the global expansion and development of the Company's cross-border social e-commerce business, comprising 40% or approximately HK$45.1 million for overseas market expansion in Europe (particularly Northeast Europe) and the Middle East; 30% or approximately HK$33.8 million for developing existing self-developed brands; and 10% or approximately HK$11.3 million for funding R&D to continuously upgrade and iterate the Company's "Giikin" system through enhanced application of AI and data technology; 10% or approximately HK$11.3 million for optimizing the existing supply chain network and expanding the scope of the Company's paper-based fast-moving consumer goods packaging business; and 10% or approximately HK$11.3 million for working capital and general corporate purposes of the Company and its subsidiaries. The Company expects the net proceeds from the Placing to be fully utilized by the end of 2027.

The Board considers that the Placing provides an effective and timely fundraising opportunity while diversifying the Company's shareholder base. The net proceeds from the Placing will strengthen the Group's financial position by providing necessary funds to support the Company's cross-border social e-commerce business and paper-based fast-moving consumer goods packaging business. The Directors consider that the terms of the Placing Agreement (including the placing price) are fair and reasonable and in the interests of the Company and shareholders as a whole, and that the Placing Agreement was entered into on normal commercial terms after fair negotiation between the Company and the placing agents.

The Company was listed on the Main Board of the Hong Kong Stock Exchange on May 27, 2025. The net proceeds from the global offering were approximately HK$426.9 million. As of June 30, 2026, approximately HK$71.0 million of the IPO net proceeds remained unutilized, while the funds allocated for the expansion of the Company's cross-border social e-commerce business in Asia, Europe and Latin America had been fully utilized. The Company has not conducted any equity fundraising activities in the 12 months immediately preceding the date of the announcement.

CapAllianz Holdings: Proposed Acquisition of BODY-MIND Wellness Project, to Issue 2.2 Billion Shares as Consideration

Wed, 15 Jul 2026 09:54:35 GMT

NewTimeSpace News: On 14 July 2026, CapAllianz Holdings issued an announcement that the Company has entered into an agreement with Origin of Self (S) Pte. Ltd. to acquire the BODY-MIND wellness project and related prepayments, for an aggregate consideration of SGD 3.8 million.

SGD 2.42 million of the consideration will be settled via the issuance of 2.2 billion shares, while the remaining SGD 1.38 million will be paid in the form of earn-out payments.

NewTimeSpace

Going Global Weekly Report: Pharma Firms Sealed Licensing Deals at a Fast Pace as Semiconductors and E-Commerce Accelerate toward HK Listings - 20260904

Outbound M&A

Outbound Partnerships

Outbound Financing

Regulation and Compliance

Overseas Operating Data

NewTimeSpace Overseas Watch

SBP GROUP (01177.HK): FDA Approves IND Application for Self-Developed Class 1 Drug TQB6426 "GPC3 ADC" for Advanced Malignant Tumors

CMS (00867.HK): China NDA Approval for Ruxolitinib Phosphate Cream in Atopic Dermatitis Adds a Second Indication

KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia

KEYTOP PARKING (02272.HK): Files Application for H-Share Full Circulation, Plans to Convert All 2,857,040 Unlisted Shares into H Shares on the Main Board

HAIXI PHARMA (02637.HK): Oral Retinal Disease Drug HX9428 Files Phase IIa IND for Diabetic Macular Edema; Phase I Data in nAMD Disclosed

HONGHUA GROUP (00196.HK): Subsidiary Signs Drilling Rig Sales Agreement Worth RMB 600 Million with Middle East Customer

PEGBIO CO-B (02565.HK): Enters Joint R&D Collaboration with SN BioScience for Long-Acting Metabolic Disease Peptides

LAEKNA-B (02105.HK): First subject enrolled in Phase I clinical study of LAE118 for advanced solid tumours

SBP GROUP (01177.HK): Enters Exclusive Licensing Agreement with Cipla for TQB2102, with Deal Value Up to USD 123 Million

Going Global Weekly Report: Innovative Drugs Win Dense FDA Clearances; SHEIN and Mech-Mind Lead the Hong Kong Listing Wave - 20260828

Outbound M&A

Outbound Cooperation

Overseas Projects and Operations

Overseas Orders and Contract Wins

Outbound Financing

Regulatory and Compliance

NewTimeSpace Going-Global Observations

WEI YUAN HLDG (01343.HK): Accepts JTC Consent Letter for Redevelopment of New Headquarters in Singapore, Plot Ratio Raised to 1.40

Wai Chun Bio-Technology (00660.HK): Signs MOU for Strategic Cooperation on AI Data Centre in Pahang Aviation City, Malaysia

Jiaxin International Resources (03858.HK): Signs Bakuta Mining Construction Contract Worth Approximately RMB 257 Million

YANCOAL AUS (03668.HK): Raises Annual Cap under Glencore Coal Sales Framework Agreement to USD 750 Million

SUNSHINE OIL (02012.HK): Subsidiary Holds 40% Stake in New Joint Venture to Build 6,000P Computing Power Centre

Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821

Overseas Cooperation

Overseas Projects and Operations

Overseas Financing

Regulation and Compliance

NewTimeSpace Going Global Observation

5100 XIZANG (01115.HK): Grants Exclusive Distribution Rights in Malaysia, Expanding into Southeast Asian and Middle East Premium Water Markets

CHINAGOLDINTL (02099.HK): Engages SRK to Advance Independent NI 43-101 Feasibility Study for Changshanhao Underground Development, Pre-Development Works Commence

SHOUGANG CENT (00103.HK): Signs Cooperation Letter of Intent with Beauty Realm Capital, Plans Joint Venture to Expand Global Industrial Rayon Market

SINOPEC SSC (01033.HK): Wholly-Owned Subsidiary to Acquire 50% of Mexico DS for USD 4 Million, with Follow-on Investment of up to USD 212 Million

WERIDE-W (00800.HK): H1 Revenue Up 73.3% to RMB 345.9 Million, Overseas Revenue Up 154.4%

HANKING GOLD (03788.HK): Mt Bundy Gold Project Mill Construction Commences, to Be the Largest Gold Mill in the Northern Territory

The United Laboratories International (03933.HK): UBT48128 Tablets Obtain US FDA Clinical Trial Approval

Frost & Sullivan and LeadLeo Release Landmark 2026 AI Agent Report; YouLianCloud Named Among the Chinese Agents with the Greatest Global Development Potential

HANKING GOLD (03788.HK): EPC and EPCM contracts for 5.5 Mtpa processing plant of Mt Bundy gold project awarded to two contractors, with aggregate contract value of approximately AUD 120.98 million

CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval

MINTH GROUP (00425.HK): Groundbreaking ceremony held for new production plant in Alabama, US; planned phased investment of approximately USD 430 million

Wai Chun Bio-Technology (00660.HK): Appointed Exclusive Overseas General Agent for China's Leading Crane Manufacturer; Three-Year Agreement

Kinetic Development (01277.HK): South Africa Makhado Project Commences Production on 1 August; 280kt Coking Coal Expected in 2026

HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China

Chery Automobile (09973.HK): July 2026 Sales Reach 261,876 Units Across Five Brands, Up 24.1% YoY; NEV Sales at 119,441 Units

CWT International (00521.HK): Joint Venture Established for Redevelopment of Singapore Property with Total Capital Contribution of Approximately SGD 51.75 Million

Chifeng Jilong Gold Mining Group (06693.HK): Significant Resource Update for Sepan SND Project of Vientiane Mining in Laos, Total Gold Equivalent Metal Volume Reaches 260 Tonnes

HSBC Holdings plc (00005.HK): Disposal of Australian Residential and Personal Loan Portfolio for A$36 Billion

ASCOTT: Secures 9 Projects in Vietnam in H1 2026, Adding Over 3,200 Units

CIMIC Group: UGL Secures Stage 2 Contract for Neoen’s Goyder Battery Energy Storage Project in South Australia

CONCORD HC GP(02453.HK) Signs Cooperation Agreement with Ministry of Health of Uzbekistan to Jointly Build and Operate Gamma Knife Radiosurgery Centre

iWOW Technology Completes Approximately SGD 15 Million Placement to Accelerate Expansion of AgeTech and Clinical Nutrition Businesses

IPS Securex Holdings: Awarded SGD 1 Million Contract for Data Centre Security Systems

Keppel REIT to Sell Tokyo KR Ginza II Asset for Approximately JPY 11.52 Billion at a 9.7% Premium

Home Control (01747.HK): Signs Strategic Cooperation MOU with Articura on Indonesia Localized Healthcare AI

EUROEYES (01846.HK): Completes Acquisition of Dutch Refractive Surgery Group at Consideration of Approximately EUR131 Million; Reallocates Proceeds to Prioritise European Expansion

Observations on HKIC's 2025 Annual Report: Building a Comprehensive RISC-V Ecosystem and Paving the "Belt and Road" Route for Global Expansion

Building a Comprehensive RISC-V Ecosystem to Actively Support National Technological Innovation

Paving the "Belt and Road" Expansion Route to Connect National Strategy with Global Innovation

GDS Global Secures New Contracts Worth Approximately S$6 Million in Singapore

FRASERS CENTREPOINT TRUST: Consortium Wins Tender for Mixed-Use Site at Bayshore Drive; Retail Mall Development Cost Estimated at S$613 Million

HS Optimus Holdings Completes Acquisition of 30% Stake in Medicorp Sdn Bhd

i-CABLE Communications (01097.HK): Invests US$4.5 Million in Korean Music Festival

Xiamen Jihong (02603.HK) to Place New H-shares Under General Mandate, 80% of Proceeds for Global Business Expansion

CapAllianz Holdings: Proposed Acquisition of BODY-MIND Wellness Project, to Issue 2.2 Billion Shares as Consideration

HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China